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The presence of hypoxia within tumours has significant biological and 
pharmacological implications leading to resistance to therapy and poor prognosis. 
The eradication of hypoxic cells has been a major goal for many years but despite 
decades of research, no hypoxia specific therapies have been approved for use in 
humans. The purpose of this thesis is to explore the possibility of targeting the 
glycolytic phenotype of cancers with the aim of specifically eradicating hypoxic cells.  
Initial studies using a series of glycolytic inhibitors (3-bromopyruvate, 2-
deoxyglucose and sodium oxamate) did not show hypoxia selectivity in vitro and in 
several cell lines, resistance under hypoxia (0.1% oxygen) occurred. In the case of 
the pyruvate dehydrogenase kinase 1 (PDK1) inhibitor dichloroacetate (DCA) 
however, hypoxia selectivity was observed in vitro but the magnitude of the 
sensitisation was much less than that of the hypoxia activated prodrug tirapazamine. 
Nevertheless, DCA did inhibit PDK1 leading to reduced phosphorylation of the 
pyruvate dehydrogenase complex and hypoxia selective cell kill.  
These results questioned whether glucose was indeed important for the survival of 
hypoxic cells but studies where glucose was removed from culture media confirmed 
that glucose is required for the survival of hypoxic cells in vitro. Using this model, 
mannose was also shown to be an important monosaccharide that could support the 
growth of cells under hypoxia opening up a novel avenue for future research. Finally, 
a series of novel organometallic complexes based on the metal silver were explored 
as potential glycolytic inhibitors. The silver N-heterocyclic carbene Ag8 was shown to 
be a potent and selective inhibitor of lactate dehydrogenase A (LDH-A) leading to 
reduced export of lactate from cells. Ag8 has a complex mechanism of action with 
inhibition of LDH-A being a novel mechanism.  
In conclusion, this study has demonstrated that targeting key enzymes in the 
glycolytic pathway does not generate hypoxia selective cytotoxic effects. This 
conclusion is surprising and reflects the complexity of targeting cellular metabolism. 
The identification of mannose as an important fuel for hypoxic cells opens up new 
avenues for research and the inhibition of LDH-A by organometallic complexes such 
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Chapter 1  
1.1  Introduction to the cancer problem. 
Cancer is a disease defined by an uncontrolled cell growth. The disease is common 
and represents an important cause of mortality in the world. In 2012, the World 
Health Organisation estimated that 8.2 million deaths and 32.6 million people living 
with cancer (within 5 years of being diagnosed) in the same time period occurred 
worldwide from cancer with about 4.1 million new cancer cases. The International 
Agency for Research on Cancer (IACR) and the World Health Organisation have 
provided estimates of cancer incidence and mortality rates in different parts of the 




















This figure was generated by the International Agency for Research on Cancer and 
full details of the report can be found elsewhere (www.globocan.iarc.fr). In total, the 
IACR estimated that there were 14.1million new cases of all cancer types in 2012, 
and there were also 8.2 million cancer deaths. There are clear geographical 
differences in both cancer incidence and mortality and whilst incidence is low in the 
less developed regions of the world, mortality rates are much higher reflecting poorer 
survival in these regions of the world.  
In the UK, Cancer Research UK report that approximately 357,000 new cases of 
cancer were diagnosed in 2014 and of these, over half were breast, prostate, lung 
and bowel cancers. With regards to mortality in the UK in 2014, the estimated 
number of cancer related deaths was 163,000 with over half of these deaths being 
caused by lung, bowel, breast and prostate cancers (cancerresearchuk.org). Whilst 
the overall cancer burden both globally and in the UK remains a significant problem 
for healthcare providers, there is clear evidence that the ‘war on cancer’ is having an 
impact on mortality figures. This is illustrated in figure 1.2 which clearly demonstrates 



















Figure 1.2 Age standardised incidence and mortality rates (per 100, 0000) in selected countries 
as determined by the IACR. Similar trends have been reported for other countries, full details 
of which can be found at www.globocan.iarc.fr  
In summary, whilst the cancer problem remains a significant issue for society and 
incidence is indeed increasing, the decreased mortality rates demonstrate that 
significant progress is being made. Significant challenges nevertheless remain and 
the ‘war on cancer’ is being fought on many fronts. This includes avoidance of risks 
and therefore reducing incidence, early detection with the aim of detecting the 
disease before it has spread and the development of new therapeutics that 
selectively target key aspects of tumour biology.  
1.2 Treatment of Cancer 
Therapies available for the treatment of cancer typically include surgery, 
radiotherapy and chemotherapy. Cancer patients traditionally receive treatment 
depending on the type, grade and stage of cancer including how far it has spread at 









accessible methods of characterising genetic lesions in cancer offers the prospect of 
personalised medicine that’s tailored to the needs of the individual (Ciardiello et al., 
2014). This emerging field is under development and has the potential to change the 
way patients are treated in the clinic. Surgery is often used as the first treatment to 
remove the primary tumour and a margin of surrounding normal tissue. Surgery is 
often used in combination with radiotherapy which uses high energy radiation to 
cause damage to cancer cells. Cancer patients could receive external or internal 
radiotherapy, which might be before or after their surgery to decrease tumour growth 
and target the remaining tumour cells. Surgery and radiotherapy are successful 
modalities for treating localised tumours but once the tumour has spread beyond the 
primary site, a systemic based therapy is required. Chemotherapy is the term used 
to describe the use of drugs to kill cancer cells. These drugs may be administered 
via various routes but the majority are delivered to the tumour via the bloodstream 
and as such, they have the potential to target cancer cells anywhere in the body.  
Chemotherapy for cancer can trace its origins back to nitrogen mustard derivatives 
of mustard gas used in the First World War. Since the pioneering studies of Gilman 
and Goodman in the 1940s, a number of drugs have been approved for use in 
humans (Goodman and Wintrobe, 1946). These drugs typically target the process of 
cell replication with alkylating agents, antimetabolites, anti-mitotic agents, anticancer 
antibiotics and others being widely described as ‘classical’ anticancer drugs 
(Goodman and Wintrobe, 1946). Whilst there have been considerable successes 
with the use of chemotherapy (typified by the use of cisplatin to treat testicular 








challenges to the successful treatment of cancers. The most significant barriers to 
successful treatment are toxicity to normal tissues and resistance to chemotherapy.     
Whilst toxicity to normal tissues is dose limiting and can be life threatening, a major 
issue faced by chemotherapy is drug resistance. This problem affects just about all 
anticancer drugs, including the modern targeted drugs and is a major contributing 
factor to the mortality caused by cancer (Holohan et al., 2013). Usually the term drug 
resistance applies to acquired drug resistance where changes in target biochemistry 
(reduced expression, mutations in the target gene and protein for example), 
increased drug efflux, decreased drug uptake, detoxification and reduced cellular 
response to drug induced damage occur following exposure to chemotherapy 
(Housman et al., 2014). Since the seminal work of Thomlinson and Gray in the 
1950s (Thomlinson and Gray, 1955, Dendy and Wardman, 2006), the role of the 
tumour microenvironment and hypoxia in particular in the therapy resistance 
phenotype has generated considerable interest. The adaptation of tumour cells to 
hypoxia and acidosis is now regarded as one of the driving forces behind tumour 
progression and metastasis as its association with tumour progression and a poor 
therapeutic outcome (Bertout et al., 2008, Brahimi-Horn et al., 2007).The 
development of therapeutic strategies designed to eradicate the hypoxic fraction of 
cells is therefore an important objective in cancer drug discovery.  
1.3 The hypoxic tumour microenvironment 
A key feature required for tumours to grow beyond a certain size (typically 1mm in 
diameter) is the establishment of a blood supply. As tumours progress, they undergo 








development of new blood vessels from existing blood vessels. This process is 
called angiogenesis and it is a recognised hallmark of cancer (Hanahan and 
Weinberg, 2000). The blood vessels that develop are however structurally and 
functionally different from the capillary network within normal tissues and these 







Figure 1.3 Cartoon of the structural and functional differences between the capillary networks 
within normal and tumour tissue.  In contrast to normal tissues, the vascular network in tumours is 
poorly organised and structurally abnormal leading to regions that are poorly perfused with blood. 
This creates regions where oxygen tension is low (hypoxia) and it is associated with low extracellular 
pH, low nutrients and high levels of catabolites, all of which contribute to the hypoxic 
microenvironment (Brown and Giaccia, 1998).    
In contrast to normal tissues where the capillary network is well organised and 
functionally efficient, the blood vessels in tumours are highly irregular, tortuous, have 
blind ends, premature linking of arterioles and venuoles (arterio-venous shunts), lack 
smooth muscle innervation, have abnormal pericyte coverage, have incomplete 








1998, Giaccia and Kastan, 1998). This results in a blood flow that is often poor, 
highly irregular and the vessels are 'leakier' leading to elevated interstitial fluid 
pressures within tumours (Heldin et al., 2004). All of these factors combine to 
generate a 'physiological' microenvironment within tumours, the severity of which 
increases as a function of distance from a supporting blood vessel (Quail and Joyce, 
2013). This microenvironment is characterised by hypoxia, low extracellular pH, low 
nutrient status, low cell proliferation rates and high levels of catabolites but of these, 
hypoxia is the best studied. Numerous studies have demonstrated that hypoxia is a 
common feature in many if not all solid tumours although the extent and severity is 
highly heterogenous. The definition of hypoxia together with a summary of oxygen 
tensions measured in different tumours has recently been published (Grazia 
Cipolleschi et al., 2014). These studies clearly demonstrate that oxygen tensions 
within solid tumours is significantly lower than normal tissue with pancreatic and 
prostate cancers being profoundly hypoxic. The presence of hypoxia in tumours has 
both therapeutic and biological implications, details of which are reviewed below 
1.4 Therapeutic implications of tumour hypoxia.   
As stated previously, the seminal work of Thomlinson and Gray (Gray et al., 1953, 
Thomlinson and Gray, 1955) demonstrated that the presence of hypoxia in tumours 
contributed to resistance to radiotherapy. Radiation kills tumour cells either directly 
through DNA damage or indirectly via the formation of reactive oxygen species 
(ROS) which requires the presence of oxygen. Under hypoxic conditions (<0.4% 
oxygen), increased resistance to radiotherapy occurs and it is estimated that hypoxic 








(McKeown, 2014). There is now a substantial body of evidence demonstrating that 
hypoxia plays a role in resistance to radiotherapy in the clinic (Overgaard, 2011) with 
particularly significant effects observed in cervical cancer (Höckel et al., 1996), head 
and neck cancer (Brizel et al., 1999) and soft tissue sarcoma (Nordsmark et al., 
2001). Resistance to radiotherapy is more complex than hypoxia alone but it 
nevertheless remains an important contributing factor to radio-resistance (Barker et 
al., 2015).     
  
Similarly, the hypoxic microenvironment of tumours is associated with resistance to 
chemotherapy (Shannon et al., 2003). Resistance can occur via direct effects as 
drugs such as bleomycin require oxygen to generate free radicals capable of killing 
cells (Sikic, 1986). Indirect effects include barriers to drug delivery including elevated 
interstitial fluid pressure. Furthermore, the presence of hypoxia induces numerous 
adaptations at the cellular level leading to reduced efficacy of anticancer drugs 
(Harris, 2002). Many of these adaptations are mediated by the hypoxia inducible 
factor 1 (HIF) transcription factor, details of which are described below alongside 











1.5 Therapeutic strategies designed to target hypoxic cells.  
Whilst the presence of hypoxic conditions within solid tumours  is regarded as a 
problem (Barker et al., 2015), it paradoxically provides an opportunity for the 
development of novel therapeutic strategies designed to selectively kill hypoxic cells. 
One major strategy that has been explored over the past 40 years is the 
development of bioreductive or hypoxia activated prodrugs (HAPs). These are 
prodrugs that are designed to become active only under hypoxic conditions 
(Huttunen et al., 2011). HAPs are activated by one or two electron oxidoreductases 
to intermediates that have the ability to be converted back to the parent compound in 
the presence of oxygen. For example, the one-electron oxidoreductase mechanism 
is reversible in the presence of oxygen making the prodrug radical intermediate 
unstable. In the absence of oxygen, the intermediate is stabilised and can either be 
directly toxic to cells or undergo further reactions to generate a toxic product. The 
back oxidation of the prodrug radical can form superoxide in the presence of oxygen 
and this can be toxic to cells but in the absence of this oxygen, the prodrug radical 
produces highly cytotoxic products as it reduces and fragments further (Guise et al., 
2014). In contrast, the two-electron reduction involves an irreversible mechanism 
and generally leads to a toxic metabolite that is oxygen independent with regards to 
its stability and activity. In this case, its activity is not dependent on oxygen but its 
selectivity in determined by the presence of elevated levels of two electron 









Figure1.4 Generalised scheme for the activation of hypoxia activated prodrugs. This scheme 
depicts the general mechanisms by which HAPs are activated by one-electron and two-electron 
reductions in hypoxic and aerobic tumour cells. PD, PDR and T represent prodrug, prodrug radical 
and toxin respectively and BV denotes blood vessel in the diagram. The resistance and drug 
penetration notations in the diagram illustrate the role that the microenvironment plays in reducing 
delivery of cytotoxic drugs to hypoxic cells and the fact that these cells are generally resistant to 
chemotherapy (Phillips, 2016).  
Numerous examples of chemical compounds that have been developed as HAPs 
have been described and these have been extensively reviewed elsewhere (Phillips, 











(i) Nimorazole is structurally related to misonidazole and metronidazole and belongs 
to the class of 5-nitroimidazoles. Its chemical structure and a general mechanism for 
the activation of nitroimidazoles is presented in figure 1.5. It acts as a radiosensitizer 
and it is currently being evaluated in a phase III clinical trial (NIMRAD) in 
combination with radiotherapy study against head and neck cancer, laryngeal cancer 






Figure1.5 Chemical structure of nimorazole (left) and general mechanism for the hypoxia 
selectivity of nitroimidazoles (right). Once inside the cell, the prodrug is reduced by one electro 
reductases to intermediates that can be back oxidised to the parent compound in the presence of 
oxygen. In the absence of oxygen, further reduction takes place ultimately leading to DNA damage 
(Takasawa et al., 2008).    
(ii) Tirapazamine (TPZ) is an aromatic N-oxide. Its mechanism of action is presented 
in figure 1.5 and following reduction by one electron reductases such as cytochrome 
P450, DNA damage is caused by spontaneous decay to generate an hydroxyl 
radical or an oxidising benzotriazinyl radical leading to inhibition of topoisomerase II 
(Brown and Wilson, 2004). In the presence of oxygen, the tirapazamine free radical 








hypoxia selective cytotoxic properties. Its efficacy in combination with radiotherapy 
and cisplatin chemotherapy was demonstrated with many hypoxic cell lines and with 
various in vivo studies on xenografts of human tumours (Brown and Wilson, 2004). 
Unfortunately, tirapazamine failed to demonstrate sufficient clinical evidence of 
efficacy (Jameson et al., 2010, Rischin et al., 2010). 
 
Figure1.6 Mechanism of action of tirapazamine (Brown and Wilson, 2004) 
(iii) Evofosfamide (TH-302) is a 2-nitroimidazole compound conjugated to a bromo-
isophosphoramine mustard. Its mechanism of action is shown in figure 1.7 and it has 
been shown that its effectiveness is increased in hypoxic conditions compared to 
aerobic cells in vitro. This compound also targets hypoxic tumour cells in xenograft 
models of tumours in vivo and showed promise in phase II clinical trials (Borad et al., 
2015). Unfortunately, the results of phase III clinical trials (MAESTRO trial) of TH-
302 in combination with gemcitabine against pancreatic cancer and soft tissue 















Figure 1.7 Mechanism of action of TH-302. In the absence of oxygen, the nitro group is reduced 
(and doesn’t undergo redox cycling) resulting in stabilisation of reactive intermediates that 
subsequently fragment to release the active drug (O'Connor et al., 2015) 
(iv)Tarloxotinib (TH-4000) is a prodrug that releases a potent tyrosine kinase inhibitor 
of the epidermal growth factor receptor (EGFR) under hypoxic conditions. Its 
structure and mechanism of action is illustrated in figure 1.8 and preclinical studies 
have shown it has efficacy against a number of experimental models including lung 
tumours. It is currently in Phase II clinical trials for the treatment of lung, head and 






Figure 1.8 Mechanism of action of TH-4000. The potent EGFR inhibitor TH4000E is released from 








(v) Apaziquone (EO9) is an indolequinone derivative of mitomycin C. This molecule 
is reduced by either one (such as cytochrome P450 reductase) or two electron 
reductases (such as NAD(P)H Quinone oxidoreductase 1, NQO1) and has the ability 
to target both hypoxic and aerobic tumours based on the relative amounts of one 
and two electron reductases in the tumour(Phillips, 2016). Its chemical structure and 
proposed mechanism of action is presented in figure 1.9. It has had a chequered 
history in the clinic but is currently in phase III clinical trials against superficial 
bladder cancer where it is administered intravesically as a loco-regional therapy 
(Phillips, 2016).  
 
Figure1.9 Chemical structure and mechanism of action of Apaziquone (EO9).  Reduction of the 
quinone by one-electron oxidoreductases generates the semiquinone that undergoes redox cycling in 
the presence of oxygen. In the absence of oxygen, further reduction to the hydroquinone generates 
DNA damaging species. Two electron reduction is effectively oxygen independent and in this case, 










(vi) Banoxantrone (AQ4N) is an aliphatic N-oxide metabolized by cytochrome P450 
and by the inducible NO synthase to AQ4, which is a potent topoisomerase II 
inhibitor. Its chemical structure and mechanism of action is presented in figure 1.10. 
The parent compound undergoes sequential two electron reduction to AQ4M and 
then AQ4 in a process that’s inhibited by oxygen. AQ4 inhibits topoisomerase activity 
when hypoxic cells try to enter the cell cycle following reoxygenation caused by 
partner therapeutics killing the aerobic fraction. This molecule has shown antitumor, 
anti-metastatic and antiangiogenic effects in preclinical models of cancer in 
combination with radiotherapy and phase I clinical trials were promising (Albertella et 
al., 2008). AQ4N is currently not undergoing further clinical development because of 
commercial reasons but new analogues of AQ4N are being developed by 
OncoTherics.   
 
Figure 1.10 Chemical structure of AQ4N and reductive activation to the potent topoisomerase 
inhibitor AQ4 (Phillips, 2016). AQ4N is reduced by various cytochrome P450 isoforms to the mono-
N-oxide (AQ4M) and subsequently AQ4. This process is inhibited by oxygen as it outcompetes AQ4N 
for the haem center within the CYP enzymes. The images represent cells treated with either AQ4N 








(vii) PR-104 is a nitro-aromatic ‘pre-prodrug’ and its structure and mechanism of 
action is outlined in figure 1.11. The initial reaction is removal of the phosphate group 
by phosphatases and this can occur in both aerobic and hypoxic cells. The product 
(PR-104A) is then metabolized to nitro radical intermediates which can be back 
oxidised to the non-toxic PR104A form. In the absence of oxygen, the nitro radical 
can be reduced further to generate the active products PR-104H and PR-104M. 
Reduction of PR-104A by aldo-ketoreductases (a two electron reduction step) 
bypasses the oxygen sensitive intermediate and can generate active metabolites 
under both aerobic and hypoxic conditions depending upon the enzymology of the 
tumour.  PR-104A is undergoing clinical trials against acute myeloid leukaemia and 
acute lymphoblastic leukaemia (Konopleva et al., 2015). 
 
 








1.6 Hypoxia activated prodrugs – concluding remarks 
Whilst the concept underpinning the development of HAPs or bioreductive drugs is 
elegant and attractive, the disappointing outcome of nearly 40 years of research is 
that no new drugs that are specifically designed to eradicate hypoxic cells have 
successfully been approved for use in humans as yet. Numerous reasons for the 
failure of these compounds in clinical trials have been put forward and whilst the lack 
of success is frustrating, it has provided scientists with a wealth of knowledge that 
can be incorporated into the preclinical and clinical evaluation of the next generation 
of HAPs. As described above, new HAPs are currently in clinical trial but attention is 
switching to developing alternative approaches that are designed to exploit some of 
the biological features of hypoxic cells, details of which are covered in the following 
sections.  
1.7 Biological implications of tumour hypoxia. 
As stated above, hypoxia is a key feature of the tumour microenvironment and it 
affects the biological activity of tumour cells. Tumour hypoxia plays a significant role 
in tumour progression leading to tumours becoming more invasive, aggressive and 
resistant to therapeutic agents (Vaupel and Mayer, 2007). Unlike normal tissue, the 
tumour vasculature is of poor quality and does not allow a sufficient supply of oxygen 
to tumour cells that exist some distance away from a blood vessel (Brizel et al., 
1999). The tumour regions are considered hypoxic when the oxygen partial pressure 
(PO2) is close to or less than 10 mmHg (Harrison and Blackwell, 2004). These 
hypoxic zones have been found in a large number of human tumours including 








melanoma (Yoshimura et al., 2004, Brown and Wilson, 2004, Vaupel and Mayer, 
2007). Cells that reside in hypoxic areas have to adapt to these challenging 
conditions and the master regulator of these adaptations is the transcription factor 
hypoxia inducible factor 1 (HIF1).  
Under hypoxic conditions, HIF1 becomes active and the key regulatory steps 
involved are presented in figure 1.12. HIF is complex heterodimeric protein 
composed of an α subunit that is sensitive to oxygen and a β subunit that is 
insensitive to oxygen. Under normoxic conditions, HIF-1α has only a short half-life as 
prolyl hydroxylases (PHD) and factor inhibiting HIF (FIH) add hydroxyl groups to 
proline residues 402 and 564 (in the case of PHD) and aspargine 803 (in the case of 
FIH). Hydroxylated prolines 402 and 564 are targeted by the tumour suppressor von 
Hippel Lindau (VHL) which adds ubiquitin leading to proteosomal destruction (Martin, 
2005;Maxwell, 1999). FIH adds hydroxyl groups to asparagine 803 and this prevents 
the binding of transcriptional co-activators (Poyya et al., 2017). PHDs and FIH are 
dioxygenases and do not work in the absence of oxygen and this leads to rapid 
intracellular accumulation of HIF-1α (Klaassen et al., 2013). After translocation into 
the cell nucleus, HIF-1α complexed to HIF-1β to form active HIF1, then binds to 
specific DNA sequences called hypoxia-responsive elements leading to transcription 
of the corresponding target genes (Cay et al., 1992). Numerous human and 
veterinary studies have shown a correlation between the increased expression of 
HIF-1 in tumours and the malignancy of tumours (Majmundar et al., 2010).  HIF-1 
plays a key role in controlling how cells adapt to oxygen depletion and it triggers the 








glycolytic phenotype, supports cells that have a stem cell-like phenotype and selects 










Figure 1.12 Regulation of HIF-1a and protein signalling under normoxic and hypoxic 
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HIF1 directly impacts upon a number of key biological processes and these are 
summarised in figure 1.13. Full details of its impact upon processes such as 
angiogenesis and cell survival can be found elsewhere (Walsh et al., 2014, Vaupel 
and Harrison, 2004) but the remainder of this chapter will focus on the effects of 
hypoxia and HIF1 on the metabolic phenotype of cancers. To place the effects of 
hypoxia on metabolism into context, the metabolic phenotype of cancer will be 











Figure 1.13 The impact of HIF-1α on tumour cells under hypoxic conditions. Hypoxia causes 
stabilization of the factor HIF-1α and this co-ordinates the expression of many genes involved in the 
response of tumour cells to hypoxia (Vaupel and Harrison, 2004).  
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1.8 The glycolytic phenotype of cancer – an emerging hallmark of cancer.  
In 2000, Hanahan and Weinberg proposed the concept of "hallmarks of cancer" and 
they have identified six characteristics (abnormalities) that a normal cell acquires 
during the process of tumorigenesis. These include self-sufficiency in growth signals, 
the avoidance of growth inhibitory signals, the ability to invade and metastasize, 
replicative immortality, the induction of angiogenesis and resistance to cell death. 
Four additional features were added to this list in their updated version (Hanahan 
and Weinberg, 2011) and these included the emerging hallmarks of deregulated 
cellular energetics and avoidance of immune surveillance and the enabling 
characteristics of genomic instability and tumour-promoting inflammation (Figure 
1.14).  
 
Figure1.14 The emerging hallmarks and enabling characteristics of cancer (Hanahan and 








In their 2011 article, Hanahan and Weinberg acknowledge the growing scientific 
evidence of metabolic perturbation in cancers and that as cancers develop a 
metabolic switch from oxidative phosphorylation to aerobic glycolysis frequently 
takes place. This metabolic reprogramming is now recognised as a common feature 
of many types of cancer and in some cases, mutations in genes that govern the 
expression of key metabolic proteins have been associated with oncogenic 
events(DeBerardinis and Chandel, 2016). In addition, it is now known that many 
metabolic enzymes are under the control of oncogenes, tumour suppressor genes 
and key transcription factors such as HIF1.  These facts make the metabolic 
phenotype of cancers interesting both biologically and because of the therapeutic 
opportunities it provides. 
1.9 Aerobic Glycolysis (Warburg effect) 
Like most cells, tumour cells use glucose as a major source of energy for growth and 
survival. In normal cells, mitochondrial aerobic respiration (oxidative 
phosphorylation) generates 90% of the energy for the cell in the form of adenosine 
triphosphate (ATP), whereas approximately 10% of the energy is produced by 
glycolysis. Therefore, glucose is completely catabolized via glycolysis and the citric 
acid cycle (Krebs cycle) and generates a large amount of ATP through the oxidative 
phosphorylation process. For one molecule of glucose, a total of 36 molecules of 
ATP are produced.  When oxygen levels are reduced, glucose is metabolized to 
lactate in a process known as anaerobic glycolysis, producing 2 molecules of ATP 
per one molecule of glucose. In tumour cells, they undergo metabolic reprogramming 








(figure 1.15). In a tumour, it is estimated that 85% of energy is generated by the 
glycolytic pathway despite the fact that oxidative phosphorylation is the most 
effective route for producing ATP (Jones and Bianchi, 2015, Vander Heiden et al., 
2009). Tumour cells become glucose-dependent and its consumption is increased 
and this phenomenon is called the Warburg effect (figure.1.15). 
 
Figure 1.15 Glucose metabolism in normal cells and tumour cells. Normal cells undergo 
anaerobic glycolysis only in the absence of oxygen. Cancer cells however undergo aerobic glycolysis 
even in the presence of oxygen (Vander Heiden et al., 2009).    
Nevertheless, even if the mitochondria seem to participate little in energy 
metabolism, it does not mean that the mitochondria are inactive. Indeed, it has been 








intact and that mitochondria play a key role in anaplerotic reactions via the use of 
glutamine (DeBerardinis et al., 2007).  
1.10 Glutamine metabolism 
In order to divide, a cell must duplicate its genome and provide sufficient protein and 
lipids to create a new cell. For this purpose, the cell must use common extracellular 
nutrients such as glucose or glutamine and enter them into metabolic pathways that 
convert them into biosynthetic precursors. Alongside glycolysis, cancer cells are also 
heavily dependent upon glutamine and the process of glutaminolysis (Daye and 
Wellen, 2012). As illustrated in figure 1.16A, glutamine can be metabolised by 
glutaminase (GLS) to give glutamate and this can enter into the Krebs cycle via 
conversion to α–ketoglutarate. This can then be used to replenish the oxaloacetic 
acid required to drive the Krebs cycle and allows for key intermediates such as 
citrate to be used for lipid synthesis (DeBerardinis et al., 2007). 
Alternative pathways are available as illustrated in figure 1.16B, the presence of 
hypoxia leads to the up-regulation of HIF1 and this in turn leads to an increased 
expression of pyruvate dehydrogenase kinase 1 (PDK1). PDK1 directly 
phosphorylates and inactivates the pyruvate dehydrogenase complex leading to 
reduced entry of acetyl CoA into the Krebs cycle. Under these conditions, lipid 
synthesis is still possible via the conversion of glutamine into citrate outside of the 
mitochondria as illustrated in figure 1.16B. This pathway is also possible in aerobic 



















Figure 1.16 Metabolic pathway for the biosynthesis of lipids. Panel (A) shows the mitochondrial 
function under aerobic conditions where glucose and glutamine are completely converted to acetyl-
CoA. Panel (B) shows the cancer cells using reductive glutamine metabolism to generate acetyl-CoA 
where there is a switch from glucose to glutamine metabolism due to loss of VHL or under hypoxia 











1.11 Regulation of metabolic pathways associated with the Warburg effect.  
The demonstration that various oncogenic mutations directly mediate the metabolic 
reprogramming seen in cancers has generated considerable interest amongst 
cancer biologists and the drug discovery community. Full details of the links between 
oncogenic drivers and metabolism are described in detail elsewhere (Vaupel and 
Harrison, 2004) and described briefly below and summarised in figure 1.17.  
PI3K: A major regulator of metabolism is the phosphoinositide 3-kinase pathway 
(PI3K). PI3K regulates the level of phosphorylated phosphatidylinositol 3 (PIP3) and 
it can be activated by growth factors leading to activation of downstream client 
proteins such as Akt and mTOR (Franke, 2008, Auger et al., 1989). This activation is 
important for both cell proliferation and glucose metabolism. mTOR plays a key role 
in metabolism(Shimobayashi and Hall, 2014) where cell growth is promoted by the 
stimulation of de novo synthesis of lipids, nucleotides and proteins which represent 
key building blocks for cell proliferation. In addition to its role in providing biosynthetic 
precursors for cell growth, this signalling pathway regulates the entry of glucose into 
the cell and its use. It makes the cells dependent on a high flux of glucose via the 
activation of hexokinase or phosphofructokinase(Kohn et al., 1996, Hardie, 2012) 
(Deprez et al., 1997).  
HIF1: As described above, HIF1 is a master regulator of cellular response to hypoxia 
in tumours (Clottes, 2005). HIF1 is a transcription factor involved in the regulation of 
the expression of many genes that control different cellular functions, such as 
angiogenesis, survival, invasion and metabolism (Lauzier et al., 2006). With regards 








such as 6-phosphofructo-2-kinase (PFKFB3) (Obach et al., 2004) and aldolase A 
(Semenza et al., 1996). It also contributes to an increase in intracellular glucose by 
increasing the expression of glucose transporters (GLUT1 and GLUT3) which 
mediate glucose entry into the cell (Haase, 2006, Zapata-Morales et al., 2014, Song 
et al., 2009). HIF1 also reduces mitochondrial oxidative phosphorylation by blocking 
pyruvate entry into the mitochondria by inhibiting the conversion of pyruvate to 
acetyl-CoA by pyruvate dehydrogenase (PDH). HIF1 is a transcriptional activator of 
the pyruvate dehydrogenase kinase PDK1 which inactivates PDH enzymatic activity 
by phosphorylation(Kim and Dang, 2006, Kim et al., 2006).  
AKT: AKT is an intracellular serine/threonine kinase and a downstream effector of 
the PI3K signalling pathway. It is activated through interaction with PIP3 at the cell 
membrane but can also be activated independent of PI3K activity. It is a key 
signalling molecule with over 100 reported cellular substrates.  Akt signalling is 
associated with multiple cellular effects including regulation of cell survival, 
proliferation, protein synthesis and metabolism. In normal cells Akt, which functions 
as a proto-oncogene, participates in the regulation of the balance between cell 
survival and cell death (Riemenschneider et al., 2006). One of the features of cancer 
cells is disturbance of this balance resulting in uncontrolled cell proliferation and 
enhanced cell survival (Chen et al., 2001). Interestingly, oncogenic activation of AKT 
kinase does not necessarily increase proliferation of cancer cells in culture but has 
been shown to stimulate glycolysis in the presence of oxygen (Elstrom et al., 2004). 
AKT stimulates glucose consumption without changing the oxidative phosphorylation 








AKT became dependent on glucose to survive and proliferate (Elstrom et al., 2004). 
The effects of AKT on growth and cell proliferation appear closely related to its 
impact on energy metabolism, particularly through the control of activation of 
mTORC1 (complex mammalian target of rapamycin 1). Abnormalities of the PI3K / 
AKT / mTOR pathway are important events leading to the development of a tumour 
(Riemenschneider et al., 2006). 
MYC: The oncogene Myc targets many genes that are involved in the breakdown of 
glucose to pyruvate and finally to lactate(Le et al., 2010, Hsieh et al., 2015). These 
genes include Lactate dehydrogenase A (LDHA), the glucose transporter GLUT1, 
hexokinase 2, phosphofructokinase and enolase 1. Myc also induces breakdown of 
glutamine by stimulating glutaminase, which transforms glutamine into glutamate. 
Glutamate can be excreted or enter the Krebs cycle where it is transformed into α-
ketoglutarate as described above. In cells that express the Myc oncogene, they can 
become dependent on glutamine and cells enter apoptosis when glutamine is 
removed from the culture media (Altman et al., 2016). Therefore, Myc promotes 
aerobic glycolysis and glutaminolysis in cancer cells thereby supporting the 
metabolic reprogramming observed in cancer cells(DeBerardinis et al., 2008b).  
The tumour suppressor gene p53: P53 is involved in many cell processes and is 
widely regarded as the ‘guardian of the genome’ (Lane, 1992). The diverse functions 
of p53 range from cell cycle regulation to the control of apoptotic signalling 
pathways. It plays the role of ‘controller’ in the cell that can detect stressful situations 
and depending on the severity of the stress, it can direct the cell to repair, cell cycle 








More recent evidence has demonstrated that p53 participates in the regulation of cell 
respiration via disruption  through transcriptional activation of Synthesis of 
cytochrome C oxidase 2 (SCO2) which is critical for the function of the cytochrome c 
oxidase complex and oxygen utilisation and suppresses glycolysis via TP53 Induced 
Glycolysis Regulatory Phosphatase (TIGAR) and phosphoglycerate mutase (PGM) 
(Matoba et al., 2006). In addition, wild type p53 reduces intracellular levels of 
glucose by inhibiting the expression of the glucose transporters GLUT1 and GLUT4 
(Schwartzenberg-Bar-Yoseph et al., 2004). P53 also inhibits the expression of 
pyruvate dehydrogenase kinase 2 which phosphorylates and inactivates the PDH 
complex that catalyses the conversion of pyruvate to  acetyl-CoA (Contractor and 
Harris, 2012). Thus, the inactivation of p53 is directly linked to the metabolic 























Figure 1.17 Regulation of cell metabolism in proliferating cancer cells (DeBerardinis et al., 
2008a). The figure shows several key pathways that impact upon cell metabolism and are significant 
contributors to the Warburg effect. Constitutive activation of key pathways such as PI3K, AKT, mTOR, 
Myc, and HIF1 impact upon both glucose metabolism and the uptake of essential amino acids, all of 
which contribute to metabolic reprogramming in cancers.   
1.12 Key enzymes in the glycolytic pathway 
The metabolic enzymes frequently modified in cancer may be different depending on 
the presence of specific genetic abnormalities but despite this, three key enzymes 
play an important role in the glycolytic phenotype of cancer cells. These are 
hexokinase (HK), pyruvate dehydrogenase kinase (PDK) and lactate dehydrogenase 










Hexokinase (HK): There are two isoforms of HKs, HK1 which is highly expressed in 
tissues like the brain and HK2 which is overexpressed in a number of cancers such 
as glioblastoma multiforme (GBM) and is associated with a poor prognosis (Wolf et 
al., 2011). Decreasing the expression of HK2 restores oxidative metabolism of 
glucose and enhances cell sensitivity to cytotoxic insults (Aft et al., 2002, Pedersen, 
2007). In addition, inhibition of HK2 expression in orthotopic GBM xenografts caused 
a significant a decrease in proliferation and angiogenesis (Wolf et al., 2011). 
Experimental overexpression of HK2 in cancer cells in vitro resulting in increased 
glucose phosphorylation is associated with increased cellular proliferation (Ahn et al., 
2009).  
Pyruvate dehydrogenase kinase (PDK): As described earlier, PDK is a protein that 
participates in the regulation of the pyruvate dehydrogenase complex (PDH) 
responsible for the conversion of pyruvate to acetyl-CoA which then enters the Kreb 
cycle. The regulation of PDH is highly coordinated by phosphorylation and 
dephosphorylation cycles catalysed by PDK and pyruvate dehydrogenase 
phosphatases (PDPs) respectively. PDK exists in four isoforms (PDK1-PDK4) 
(Popov et al., 1997). These kinases are found deregulated in several diseases 
especially in cancers such as colon, kidney and lung cancers. The overexpression of 
PDK1 is associated with HIF-1 stabilization (Kim et al., 2006).  
Lactate dehydrogenase (LDH): LDH is the enzyme in the glycolytic pathway that 
converts pyruvate to lactate either in the absence of oxygen (as is the case in normal 
cells) or in the presence of oxygen (aerobic glycolysis). LDH is encoded by 2 genes, 








2 polypeptide chains called the M and H subunits. There are 5 isoforms of the LDH 
(Markert and Ursprung, 1962). LDH-1 isoform is composed of 4 H subunits and LDH-
5 by 4 M subunits. LDH-5 is the most effective isoform to catalyse the conversion of 
pyruvate to lactate whereas LDH1 catalyses the conversion of lactate to pyruvate. In 
tumour cells that undergo aerobic glycolysis, increased glucose consumption leads 
to accumulation of lactate. This could lead to acidification of the tumour cell 
(intracellular pH would become acidic) but in order to maintain viability, lactate 
anions and H + ions are pumped out of the cell into the extracellular space resulting 
in the extracellular pH decreasing whilst intracellular pH is maintained at 7.4. High 
expression of LDH-5 is a poor prognostic factor in several cancers (Shim et al., 
1997, Koukourakis et al., 2003). Many studies also show that LDH-A expression is  a 
marker of tumour aggression and resistance to certain treatments (Deichmann et al., 
1999).  
1.13 Use of inhibitors to target key enzymes in tumour glycolysis (Warburg 
effect)  
A number of small molecule inhibitors of glycolysis have been described in the 
literature and their chemical structures are presented in figure 1.18. Brief details of 





















Figure1. 18 Chemical structures of known inhibitors of glycolysis.  
2-deoxy-D-glucose (2DG): 2-Deoxy-D-glucose differs from glucose by the presence 
of a hydrogen atom instead of a hydroxyl group on the C2 atom. The first step of 
glycolysis is the phosphorylation of glucose to glucose 6 phosphate by hexokinases. 
2DG can also be phosphorylated by HK to generate 2DG-phosphate, which 
accumulates in the cell and inhibits HK and therefore  glucose metabolism (Young, 
1972). (Pelicano et al., 2006). At millimolar concentrations, 2DG induces a decrease 
in the levels of ATP and cell death (Brown, 1962). This compound has entered 
clinical trial programs for the treatment of cancer in combination with other agents 
and these studies have shown that up to 250 mg/kg, 2DG is safe. It has also been 
shown to increase the effect of radiation therapy in patients with cerebral tumours 









3-Bromopyruvate (3-BP): 3-Bromopyruvate is also an inhibitor of HK leading to a 
decrease in ATP and cell death (Pedersen, 2012, Nakano et al., 2011). The exact 
mechanism is not fully understood but it is thought that 3-BP may bind to sulfhydryl 
groups of the hexokinase that are responsible for its enzymatic activity(Davidescu et 
al., 2015). This inhibitor attacks the early stages of glycolysis and causes a strong 
ATP depletion, especially in tumour cells with mitochondrial defects (Xiao et al., 
2013, Xu et al., 2005). Chen et al (2009) also demonstrated that 3-BP is able to 
dissociate mitochondrial bound Hexokinase (HK2 binds to mitochondrial VDAC 
channels) and induces apoptosis (Chen et al., 2009, Shoshan, 2012). Transport of 3-
BP into tumour cells is via lactate transporters on the cell surface (Queirós et al., 
2012). Correspondingly, Ko et al (2004) reported complete tumour response without 
side effects in rats after the intraperitoneal administration of 3-BP.  
Dichloroacetate (DCA): This molecule is known to inhibit PDK and prevent pyruvate 
entering into the Kreb cycle (Bonnet et al., 2007). DCA is already used clinically for 
the treatment of mitochondrial genetic diseases (Kaufmann et al., 2006). It is an 
analogue of pyruvate and it enters the bloodstream quickly after oral intake giving it 
good bioavailability. This molecule is transported across cell membranes by the 
monocarboxylate transporters that normally carry lactate, pyruvate or ketone bodies. 
DCA decreases tumour growth in vitro and in vivo without affecting the normal cells 
(Li et al., 2012, Stacpoole et al., 1998). DCA obtained notoriety in the popular press 
following publications in Cancer Cell(Bonnet et al., 2007) and subsequently the New 
Scientist by Evangelos Michelakis of the University of Alberta claiming that DCA was 








generated considerable interest in the public domain, clinical trials have yet to prove 
it is effective at treating cancer.   
Sodium Oxamate: Sodium oxamate is structurally similar to pyruvate and inhibits 
LDH-A competitively. The cell becomes depleted of NAD+ and glyceraldehyde-3-
phosphate accumulates. Thereby more fructose-1,6-bisphosphate is obtained 
inhibiting phosphofructokinase and thus blocking glycolysis (Goldberg et al., 1965). 
In addition to inhibition of LDH-A, sodium oxamate inhibits aspartate 
aminotransferase. The authors were also able to show that sodium oxamate 
selectively inhibits the growth of MDA-MB-231 cells compared to normal human 
epithelial cells and also slowed tumour growth in vivo (Thornburg et al., 2008). The 
blockade of LDH-A by sodium oxamate also inhibited tumour growth (B cell- 
Lymphoma and pancreas) in a mouse model (Le et al., 2010). In chemo-resistant 
breast cancer cells, inhibition of LDH-A by sodium oxamate enhanced the cytotoxic 
potency of the chemotherapeutic agent Taxol (Zhou et al., 2010) 
 
1.14 Cellular metabolism under hypoxic conditions.  
To date, the majority of studies have focused on unravelling the metabolic phenotype 
of cancers in aerobic conditions with comparatively little attention being paid to the 
metabolic properties of hypoxic cells. The effect of hypoxia on cell metabolism has 
however been reviewed in detail elsewhere (Eales et al., 2016) and key features are 









Figure1. 19 Metabolic adaptations of tumours cells to hypoxia (Eales et al., 2016).  
As the oxygen tension inside tumours decreases, the majority of metabolic 
adaptations to hypoxia are mediated by HIF1. These include up-regulation of key 
glycolytic enzymes including HK and LDH-A and transporters such as Glut-1 
(responsible for transporting glucose into the cell) and MCT4 (responsible for 
exporting lactate out of the cell). Cell proliferation can be reduced via the HIF1 
dependent up-regulation of p21WAF1/CIP1 although there are other tumours where 
cell proliferation can still occur under hypoxia through mTOR related pathways 
(DeYoung et al., 2008). HIF1 can also reduce oxidative phosphorylation by changing 
subunits within cytochrome c oxidase complex (COX4-1 replaced with COX4-2) and 








COX4-1 subunit (Semenza, 2011). Another key change mediated by HIF1 is 
upregulation of PDK1 and suppression of PDH activity thereby reducing the flux of 
carbon into the Krebs cycle (Kim et al., 2006). In addition to increased glycolysis, 
hypoxic cells with high MYC expression have elevated glutamine metabolism and 
this could support cell proliferation under hypoxic conditions (Wise et al., 2008, 
DeBerardinis et al., 2007).  
However, hypoxia is also known to induce cell apoptosis by reducing expression of 
the anti-apoptotic Bcl-2 gene or by activation of the P53 gene(Shimizu et al., 1995, Li 
et al., 1999). Normally, p53 contributes to genomic stability by inducing cell cycle 
arrest and cell death after DNA damage. In addition to this p53 participates in the 
regulation of metabolism. It is controls glycolysis by activating the expression of 
TIGAR (TP53-induced glycolysis regulator), which reduces the level of intracellular of 
fructose-2,6-bisphosphate(Bensaad et al., 2006). Moreover, p53 reduces the 
intracellular glucose by inhibiting glycolysis pathway. Therefore, Loss of p53 induces 
activation of the NF-κB, it accelerates glycolysis in tumour cells(Kawauchi et al., 
2008). 
Recent studies have shown that a high carbon fraction of fatty acids in hypoxic cells 
is not derived from glucose or glutamine, and that hypoxic cells can use another 
source (exogenous acetate) to maintain the Kreb’s cycle. Acetate utilisation can 
support lipogenesis and sustain cell growth under hypoxic conditions (Bulusu et al., 
2017, Kamphorst et al., 2014). A few years ago, Sonveaux et al identified that cancer 
cells can operate in oxidative mode producing energy from glucose and other 








produce energy. Sonveaux and colleagues also reported metabolic coupling 
between hypoxic and normoxic tumour cells with normoxic tumour cells 
oxidisinglactate (generated through glycolysis by hypoxic cells) as a source of 
energy, which enables availability of glucose for hypoxic / glycolytic cancer cells to 
survive (Figure 1.20). This type of behaviour has been demonstrated in many human 











Figure 1.20 summarizes metabolic coupling of aerobic tumour cells and hypoxic tumour cells 








1.15 Rationale and aims of this study 
The altered metabolism of cancer cells was first described by Otto Warburg in the 
1930s and is a specific and key feature of cancers. This emerging hallmark of 
cancers offers many therapeutic opportunities and this is particularly true in the 
context of the hypoxic microenvironment. The switch to a highly glycolytic phenotype 
under hypoxic conditions suggests that inhibitors of glycolysis should be 
preferentially active against hypoxic cells and this hypothesis will be tested in this 
thesis. In view of the failure of HAP technology to eradicate hypoxic cells, there is a 
clear need for new therapeutic approaches for targeting cancer cells in the hypoxic 
microenvironment.  
The principle aim of this thesis therefore is to determine whether or not established 
inhibitors of cellular metabolism are preferentially active against hypoxic tumour cells 
compared to aerobic cells. The inhibitors used and the enzymes they inhibit are 
illustrated in figure 1.20. In addition, it is known that alternative carbon sources such 
as lactate and acetate can be used to support the growth of tumour cells and this 
thesis will also explore whether other sugars than glucose can serve as carbon 
sources to support the growth and/or survival of tumour cells under hypoxic 
conditions. Finally a series of novel organometallic complexes based on silver N-
heterocyclic carbenes (NHC) will be investigated as potential inhibitors of key 
enzymes in the glycolytic pathway. The rationale for this is based on preliminary 
studies showing that silver NHC complexes can inhibit glycolysis (Allison et al 2017). 
It is not clear however where in the glycolytic pathway these inhibitors might work 








enzymes such as HK, PFK and LDH-A.   
 
 
Figure 1.21 Overview of the compounds used in this thesis and their sites of action in the 









Materials and general methods 
2.1 Materials  
All chemicals were obtained from Sigma Aldrich unless otherwise stated. This 
includes: 3-bromopyruvate (3BP), 2-Deoxy-D-glucose (2DG), Sodium Oxamate, 
Gossypol, Sodium Dichloroacetate (DCA), Dulbecco’s Modified Eagle Medium 
(DMEM), Sodium Pyruvate, Roswell Park Memorial Institute 1640 medium (RPMI 
1640), Foetal Bovine Serum (FBS), L-glutamine, trypsin (0.05%)/EDTA (0.02%), 
Phosphate Buffered Saline (PBS) tablets, Tetrabutylammonium Sulfate, Dimethyl 
Sulphoxide (DMSO). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) was obtained from Alfa Aesar chemicals. HPLC grade Acetonitrile was 
obtained from Fisher Scientific.  
2.2 Cells and cell culture conditions 
Unless otherwise stated, all cell lines were initially purchased from the American 
Type Culture Collection (ATCC) or the European Collection of Authenticated Cell 
Cultures (ECACC) and stored in the cell culture bank at the University of 
Huddersfield. These included the human colorectal cancer cell lines SW48, LS123, 
HT29, BE (obtained originally from Dr Tim Ward, Paterson Institute for Cancer 
Research, Manchester), HCT116 p53-/- and HCT116 p53+/+ (both obtained from 
Professor Bert Vogelstein, Johns Hopkins University, Howard Hughes Medical 
Institute, USA). HT-29 and BE cells were maintained in RPMI 1640 supplemented 








HCT116 p53+/+ and SW48 cells were maintained in DMEM supplemented with 10% 
FBS, 2mM L-glutamine and 1mM sodium pyruvate. Similarly, human non-small cell 
lung cancer A549 cells were maintained in DMEM supplemented with 10% FBS, 
2mM L-glutamine, and 1mM sodium pyruvate. The LS123 cell line was maintained in 
EMEM medium supplemented with 10% FBS, 2mM L-glutamine, and 1mM sodium 
pyruvate. The human pancreatic cancer cell line Panc10.05 was maintained in 
RPMI1460 with same supplements as above. Normal human retinal pigment 
epithelial (ARPE19) cells were cultured in DMEM/F12 supplemented with 10% FBS 
and 2mM L-glutamine. All cells were maintained as monolayer cultures at a constant 
temperature of 37°C in a CO2 enriched (5%), humidified atmosphere.  
2.3 Recovery of cell lines from storage in liquid nitrogen. 
A frozen vial of each cell line suspended in freezing medium (10% DMSO, 20% 
FBS and 70% medium) was removed from liquid nitrogen storage. Cells were rapidly 
thawed and transferred into a sterile universal tube containing 5ml of pre-warmed 
medium. Following centrifugation at 800 rpm for 5 minutes, the supernatant was 
removed and the cell pellet gently re-suspended in fresh medium. The cells were 
plated into a T25 flask and incubated at 37°C in a humidified CO2 enriched 
atmosphere. When the cells were 70-80% confluent, they were sub-cultured and 









2.4 Routine maintenance and sub-culturing of cells   
All work was carried out in class II biological safety hoods under aseptic conditions. 
Medium from the cell culture flask was removed and cells were washed with 10ml of 
sterile PBS. After washing, PBS was removed and cells were detached from the 
flask by adding 3ml of 1X trypsin EDTA solution. The flask was returned to the 
incubator and allowed to incubate for approximately 5 minutes at 37°C or until the 
cells completely detached. Once detachment was complete, pre-warmed medium 
was added into the flask to stop the activity of trypsin. The cell suspension was 
collected from the flask and placed in a sterile universal tube (50ml falcon tubes) and 
centrifuged at 800 rpm for 5 minutes to pellet the cells. The supernatant was 
removed and the cell pellet was re-suspended in 10ml cell culture medium. The cells 
then were seeded into the appropriate sized flask to maintain the culture or used for 
experiments. 
2.5 Cell counting using a haemocytometer 
Both the haemocytometer and its coverslip were cleaned with 70% ethanol prior to 
adding the coverslip onto the haemocytometer slide. The coverslip was pressed 
firmly onto the haemocytometer until Newton rings appeared. Cells were trypsinised 
and the suspension of cells was mixed by gentle repeat pipetting. Subsequently, 
each side of the haemocytometer chamber was gently filled with approximately 10µl 
of cell suspension from the edge of the chamber. The cells were counted in the 
central chamber and the 4 corner chambers. Cells were counted in a total of 10 
chambers and the average number of cells per chamber was determined. This was 








method of counting cells that crossed the boundaries of the haemocytometer 
chamber is presented in figure 2.1. For the cells that touched the outside boundaries 
of squares, the right side and bottom of boundaries were counted, whereas the cells 
that touched left and top of boundaries squares were not counted. However, the cell 












Figure 2.1 Cell counting using the haemocytometer. In each chamber (consisting of 16 squares in 
this example) cells that crossed the left hand side and the top of the chamber were not counted 
(marked with an X in the figure). Cells on the bottom and right hand side of the chamber (marked with 








2.6 Chemosensitivity studies 
2.6.1 Validation of the MTT assay 
Briefly, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
is one of the most widely used colorimetric assays for measuring cellular response to 
drugs. It is a metabolic activity assay that relies on the conversion of MTT to a 
coloured formazan product by enzymes present in the mitochondria of cells 
(Marshall et al., 1995, Riss et al., 2016). Initial validation of the assay was based on 
determining the relationship between cell number and absorbance of the formazan 
product.  
Cells (HT29, HCT116 p53+/+ and BE) were sub-cultured as described above and a 
cell suspension of 5.7X105 cells/ml was prepared.  Cells were seeded into 96 well 
flat bottom plates with various numbers of cells per well as follows:  To lane 1 (rows 
A to H), complete medium (200 µl/well) was added to serve as a blank. To lane 2 
(rows A to H), 200 µl of cell suspension was added and to each subsequent lane, the 
volume of cell suspension added reduced by 20 µl (figure 2.2). In all cases, the final 
volume in each well was made up to 200 µl with complete medium. The cells were 
immediately treated with 20 µl of MTT (5mg/ml) and incubated for 4 hours at 37 °C in 
humidified air with 5% CO2. After the incubation period, medium was carefully 
removed and formazan crystals were dissolved with 150 µl of DMSO. The optical 
density was then determined at 550 nm using a Tecan Infinite F50 microplate reader. 
The true absorbance of each lane was determined by subtracting the absorbance of 
the blank and this was plotted against cell number. The experiment was repeated 















Figure 2.2 Schematic showing MTT validation experimental design, which is characterized by 
growing HT-29, HCT116 p53+/+ and BE cell lines on 96 well plates at different cell numbers per well. 
Cells were incubated for 4 hours with 20µl of MTT (5mg/ml). Lane 1 rows (A-H) treated as blank 
containing media only.  
2.6.2 Chemosensitivity studies under aerobic or hypoxic conditions 
(continuous drug exposures). 
Cell survival of HT29, BE, HCT116 p53+/+, HCT116 p53-/-, PANC10.05, LS123, 
SW48 and ARPE19 cells following continuous exposure to a series of 
glycolytic/metabolic inhibitors was determined using the MTT assay. Cells were 
seeded into 96-well flat bottom plates at a final concentration of 2000 cells per well in 
appropriate culture medium. In addition, HCT116 p53+/+ and HCT116 p53-/- cells 
were also seeded in RPMI 1640 medium to determine whether cellular response was 
influenced by the cell culture medium. For studies conducted under normoxia, plates 
were incubated under standard conditions of 37 °C in humidified air with 5% CO2. 








Scientific, Shipley, UK) which provides a stable atmosphere of humidified gases 
consisting of 5% CO2, 0.1% oxygen with the remainder made up with nitrogen. The 
chamber is also heated to maintain a temperature of 37oC. In both cases, cells were 
seeded into 96well plates and incubated under normoxic or hypoxic conditions for 24 
hours prior to drug exposure. 
For drug exposure, medium was carefully removed from each well and replaced with 
medium containing a various concentration of inhibitor.  Details of the inhibitors used 
and their preparation is presented in table 2.1. Plates were set up for each 
compound as follows; lane 1 (rows A to H) media only (200μl/well) to serve as the 
blank. Lane 2 (rows A to H) contained cells and culture medium with no drug 
(200μl/well) and this served as the control. Lanes 3 to 12 contained medium with 
different concentrations of drug with increments increasing as illustrated in figure 2.3. 
A range of drug concentrations was used for each inhibitor, details of which are 
specified in the results section of the thesis. In all cases, a 2-fold serial dilution 
strategy was used to prepare drug concentrations. Following the addition of drugs to 
wells (200μl/well), plates were incubated at 37oC for 96 hours before cell survival 
was assessed using the MTT assay. As described above, 20µl of 5mg/ml MTT 
solution was added to each well and allowed to incubate for 4hours in the incubator 
at 5% CO2 and 37°C. The cells were processed as described above and cell survival 
was determined by dividing the true absorbance of the treated wells by the true 
absorbance of the controls (expressed as a percentage). Cell survival was plotted 
against drug concentration to generate a dose response curve and the IC50 








treatment. All experiments were repeated a minimum of three times and the results 
were expressed as the mean ± standard deviation.  In the case of gossypol where 
the compound was dissolved in DMSO, stock solutions were prepared at 50mM in 
DMSO and stored at -20oC. The final concentration of DMSO used to treat cells was 
0.2% (v/v). This concentration of DMSO was not toxic to cells following a 96 hour 






















Table2. 1 Concentrations and chemical structures of glycolysis inhibitors used to 
target the glycolytic pathway of colon cancer cells under hypoxic and aerobic 












































































Figure 2.3 Schematic of the plate layout used to assess chemosensitivity. Lane 1 rows (A-H) 
treated as blank containing media only; lane 2 (rows A to H) represents controls; lanes 3 to 12 (rows 
A to H) represent treated lanes with each lane (rows A to H) being a single drug concentration (ie 8 
replicates per drug concentration were used).     
2.6.3 Chemosensitivity studies using short-term drug exposures.  
The response of HT29, BE, HCT116 p53+/+ and HCT116 p53-/- cells following short 
term exposures to DCA was measured using a slightly modified assay to the one 
described above. Setting up the plates and the pre-drug exposure incubation period 
was identical to the procedures above but following the addition of drugs, timed 
exposure periods were used. These were 1, 2, 4, 6, 8, 12 and 24 hours. After drug 
treatment, medium was removed and cells were washed twice with PBS before the 
addition of complete culture medium (200μl/well). Cells were then incubated at 37oC 
for up to a maximum of 96 hours prior to the addition of MTT and assessment of cell 








2.7 Cell assays 
2.7.1 Quantification of cell number and viability 
In addition to chemosensitivity assays, several cell-based mode of action assays 
were performed. Effects on cell number and viability of different drug treatments 
were analysed using an NC3000 image cytometer (Chemometec) and a predefined 
‘ViaCount’ assay (Chemometec) following the manufacturer’s recommended 
protocol.   In brief, this assay uses to determine cell viability of suspension cell 
samples. Via1 cassettes contain two different dyes; acridine orange stain (stains 
viable cells) and DAPI satin (stains non-viable cells).  
 2.7.2 Induction of Apoptosis   
Loss of mitochondrial membrane potential was assayed as an indicator of early 
apoptosis induction in cancer cells in response to drug dose (Saelens et al., 2004, 
Elmore, 2007). This assay uses the mitochondrial membrane potential stain JC1 with 
levels of red and green JC1 quantified using the NC3000 image cytometer 
(Chemometec). Cells were grown in complete DMEM medium at 5 × 105 cells/flask 
in T25 flasks and incubated for 24 hours. Cells then were exposed to DCA at 75mM 
along with the untreated control and the cells were treated for different incubation 
time periods (24, 36, 48, 60 and 72 hours); (single -dose  was used  relevant to the 
influence of DCA cytotoxicity on cancer cell at different time). Post treatment with 
DCA, cells were harvested at each time point and washed with PBS. Cells were 
detached with 1x trypsin EDTA, and the suspension of cells was centrifuged at 








counted using Via1-Cassettes (Chemometec) and 1x10^6 cells were stained with 
12.5μl of JC-1 reagent (5, 5, 6, 6-tetrachloro-1, 1, 3, 3-tetra-
ethylbenzimidazolocarbocyanine iodide) and Solution 8 containing 1 µg/ml DAPI in 
PBS according to manufacturer’s instructions (Chemometec). 10 µl of JC-1 stained 
cells were loaded into a slide chamber (NC-slide A8) and analysed using the 
NC3000 image cytometer.  
2.8 Western blotting  
2.8.1 Sample preparation  
On the day prior to treatment with DCA, cells were inoculated into T25 flasks at a 
seeding density of 2.75 X 105 and immediately placed either in hypoxic (0.1% 
oxygen) or aerobic conditions. Following 24 hour incubation at 37°C to allow cells to 
adhere, cells were treated with DCA at concentrations ranging from 0 - 20mM and 
these were incubated at 37°C, 5% CO2 humidity for 72 hours. Cell were harvested 
by removing medium from the flasks, washing three times with 5ml of PBS prior to 
the addition of trypsin-EDTA (1ml). The cells were then incubated at 37°C for 5 min, 
transferred to a centrifuge tube and centrifuged (1000 rpm, 3min room temperature). 
The supernatant was then removed and the cell pellet was then washed twice with 
cold PBS. After the final wash with PBS, the supernatant was removed and the pellet 
re-suspended in protein lysate buffer (RIPA buffer and a 1:100 dilution of protease 
cocktail inhibitor). The lysate from each tube was transferred to a 1.5ml Eppendorf 
tube and incubated on ice for 10 min prior to sonication using a probe sonicator 
(Sonics & Materials Inc) for 1 minute. Finally, cell lysates were aliquoted into new 








2.8.2 Measuring protein concentration (BCA assay)  
Total protein concentration in cell lysates was determined by using a commercially 
available protein assay (BCA, Pierce). A provided stock solution of BSA (2mg/ml) 
was diluted to give a range of concentrations of BSA standards to generate a 
standard curve. In a 96-well plate, 10 μl of distilled water was introduced into 4 wells 
(serving as the blanks), then the standards and samples were pipetted as 
quadruplets according to the pipetting scheme shown in figure 2.4. 200μL of BCA 
reagent (made up of 50 parts of reagent A with 1 part of reagent B) per well was 
added. After an incubation period (30 min), the plate was measured in the Tecan 


























Figure 2.4 Typical layout of the plate for conducting the Pierce BCA protein assay. The plate 
contains the blanks, BSA calibration curve and cell lysates.  
2.8.3 SDS-PAGE electrophoresis 
Following protein concentration determination, the samples (20 μg) were mixed with 
4x Laemmli’s SDS loading buffer and denatured at 95°C for 5min.  Proteins were 
resolved using self-casted gels (15% SDS polyacrylamide resolving gel, with a 4% 
stacking gel) in a Mini-PROTEAN® Electrophoresis cell (Biorad). Protein molecular 
weight markers (8μl) were loaded in the first well, after which the samples (20μl) 
were loaded onto the gel. The electrophoresis was started with a constant voltage of 




























































































































         








2.8.4 Electrophoretic transfer of proteins 
After electrophoresis was complete, proteins were transferred to nitrocellulose 
membrane using the Mini Trans-Blot® Electrophoresis Transfer cell (Biorad) in 1 x 
transfer buffer (10x transfer buffer (Tris base and glycine), methanol, ultrapure water 
and 10% SDS).  All membrane and filter paper was pre-soaked in 1x transfer buffer 
for 30min. The ‘sandwich’ chamber was assembled from cathode to anode as 
follows and illustrated in figure 2.5; blotting pad, 2x filter papers, the gel, a 
nitrocellulose membrane, 2x filter papers and blotting pad. All were clamped tightly 
together into the Biorad sure lock apparatus, which was positioned in the tank and 
submerged in transfer buffer. The proteins were transferred to the membrane at a 



















Direction of protein transfer 
Sponge  Filter paper   
Gel   
Nitrocellulose membrane   













2.8.5 Blocking and immune-detection  
Once transferred to nitrocellulose paper, the membrane was then blocked in blocking 
buffer (5 % powdered milk dissolved in TBS-T(1x Tris buffer saline and 0.1% 
Tween20) ) at room temperature on rocking platform at 70rpm for 1 hour to minimize 
non–specific background staining by primary and secondary antibodies. Membranes 
were incubated overnight with the appropriate primary antibody at 4°C (see table 2.2 
for details of all antibodies used) using an antibody dilution recommended by the 
manufacturer. After washing 3X with TBS-T buffer (TBS with 0.05% (v/v) tween20) or 
PBS-T for 5min, the membranes were incubated with appropriate secondary 
antibody solutions diluted at 1:10000 in blocking buffer for 1 hour at room 
temperature (table 2.2).  The membranes were then washed 3 times with TBST or 
PBS-T as recommended. The membranes were visualized using an Odyssey infra-


















Table 2 2. List of primary and secondary antibodies. 
 





Dilution  Company Catalogue 
number  
PDK-1 Rabbit  47kDa 1:1000 Cell Signalling 
technology 
mAb3820 
PDK-2 Mouse 46kDa 
1:1000 
Proteintech 15647-1-AP 
PDH Mouse  43kDa 
1:1000 
Abcam Ab110330 
PDH-P Rabbit  43kDa 
1:1000 
Abcam Ab92696 





B-actin  Mouse 44kDa 
1:50000 
Millipore MAB1501 
PMM2 Mouse 23kDa 
1:1000 
Abnova H00005373-A01 




Secondary antibodies table:   
 
Species Isotype  Dilution  Company  Catalogue number 
Rabbit IgG 1:10000 Rockland 611-145-122 











Chapter 3. Evaluation of metabolic inhibitors as hypoxia selective agents 
3.1 Introduction 
According to the Warburg hypothesis, many malignant cells generate their energy 
via glycolysis, even in the presence of oxygen instead of using much more efficient 
oxidative phosphorylation. Cancer cells relying on glycolysis has been classified as a 
feature of the tumour microenvironment and would be expected for those cancer 
cells in hypoxic regions where oxygen is less available. This metabolic change in the 
cancer cells, whilst inefficient in generating ATP, not only gives them a proliferative 
advantage because of the provision of substrates for synthesis of lipids or 
nucleotides, but also may provide resistance to apoptosis. This chapter investigates 
the effect of glycolytic inhibitors and the PDK inhibitor DCA on hypoxic cancer cells 
and whether by potentially shifting the energy metabolism of tumour cells towards 
oxidative phosphorylation this could inhibit their growth and/or promote their cell 
death.  In addition, several novel Akt inhibitors are evaluated for selective activity 













3.2 Additional methods 
3.2.1 High Performance Liquid Chromatography (HPLC) 
The stability of DCA was assayed using HPLC with a UV detector. DCA (9.73 mg) 
was dissolved in 2 ml of ultrapure water at room temperature. DCA solutions of 
known concentration were used to create a calibration curve at concentrations 
ranging from 1mM to 15.6mM. The DCA stability in culture medium at 37°C was 
examined over a 24 hour period. At various time points, the medium was collected 
into separate Eppendorf tubes and mixed with an equal volume of acetonitrile (1:1). 
Precipitated proteins were pelleted by centrifugation at 16,000 rpm for 5 min, the 
supernatant collected and then filtered through a 0.45μm membrane filter. 
Separations of the supernatant post acetonitrile precipitation were performed using a 
Beckman System Gold HPLC 166 pump, which used isocratic mobile phase (A) 
0.005M tetrabutylammonium sulfate in HPLC water and (B) methanol onto a Kinetex 
Reversed Phase 5µm C18, 250 x 4.6 mm Column. DCA peaks were detected at a 











3.3 Results  
3.3.1 Validation of the MTT assay 
Before starting MTT chemosensitivity testing, the relationship between cell number 
and absorbance was determined using HT-29, BE and HCT116 p53+/+ cells to 
confirm the validity of this assay for cytotoxicity screening. The results of these initial 
experiments are presented in figure 3.1. The results demonstrate that a linear 
relationship between cell number plated and absorbance exists for all three cell lines. 
Furthermore, there are inherent differences in the ability of cells to convert MTT to 
formazan with HCT116 p53+/+ cells appearing more proficient than BE cells. The 
results demonstrate that the absorbance is proportional to viable cell number and is 










Figure 3.1 Relationship between cell number and absorbance in the MTT assay. Three cell lines 
are presented here; HCT116 p53+/+ (  ), HT-29 (  ) and BE (  ). Each value represents the mean  









3.3.2 Determine the different of cancer cells grown under aerobic and hypoxic 
condition. 
The response of cells following continuous exposure to hypoxia (0.1% oxygen) and 
aerobic conditions is presented in figure 3.2. The result demonstrate that all cell lines 
do not grow as well under hypoxic conditions compared to aerobic conditions. In 
comparison to aerobic conditions, continuous exposure to hypoxic conditions 
resulted in growth inhibition ranging from 65% (HCT116 p53+/+) to 15% (HCT116 










Figure 3.2 Percentage of cell survival of untreated cancer cell line under aerobic and hypoxic 
condition. Each value represents the mean  standard deviation for three replicates. Black bar 









3.3.3 Response of HCT116 p53+/+ cells to tirapazamine under aerobic and 
hypoxic conditions. 
The response of HCT116 p53+/+ cells to tirapazamine was assessed following a 96hr 
treatment period under normoxic and hypoxic conditions. Tirapazamine was used as 
a positive control to ensure experimental conditions were suitable for the evaluation 
of glycolytic inhibitors. Figure 3.3 presents dose response curves for treated cells 
under aerobic (blue) and hypoxic (red) conditions. Tirapazamine was significantly 
more cytotoxic against cell under hypoxic conditions compared to normoxic 
conditions. For normoxic conditions, IC50 values against cancer cells were 11.85 ± 









Figure 3.3 Response of HCT116 p53+/+ following a continuous 96-hour exposure to 
tirapazamine under aerobic (blue) and hypoxic (red) conditions. Each value represents the mean 








3.3.4 Response of a panel of cell lines to DCA under aerobic and hypoxic 
conditions 
The response of a panel of cancer cell lines and non-cancer cells to the PDK 
inhibitor DCA was assessed by using the MTT assay after a 96hr treatment period 
under normoxic and hypoxic conditions. Six colorectal cancer cell lines (HCT116 
p53+/+, HCT116 p53-/-, HT29, BE, LS123 and SW48), one pancreatic cancer cell line 
(PANC 10.05) and one non-cancer cell line ARPE-19 were investigated. Figure 3.4 
and Figure 3.5 represent cytotoxicity dose responses of treated cells under aerobic 
(blue) and hypoxic (red) conditions. DCA was significantly more cytotoxic against 
some of the tested cell cancer lines under hypoxic conditions compared to normoxic 
conditions. For normoxic conditions, IC50 values against cancer cells ranged from 
~19.5 - 45.2 mM whereas under hypoxic conditions IC50 values ranged from ~7.15 - 











 Figure3. 4 Response of HCT116 p53+/+ (A), HCT116 p53-/- (B), HT-29 (C) and BE (D) following a 
continuous 96 hour exposure to DCA under aerobic (blue) and hypoxic (red) conditions. Each 











Figure3. 5 Response of PANC 10.05 (A), LS123 (B), SW48 (C) and ARPE-19 (D) following a 
continuous 96-hour exposure to DCA under aerobic (blue) and hypoxic (red) conditions. Each 











3.3.5 Hypoxia cytotoxicity ratios (HCR) and selectivity ratios (SR) based upon 
the 96-hour continuous DCA exposure data set.  
A summary of the IC50 data obtained for each cell line under hypoxic and normoxic 
conditions is presented in figure 3.6. Further analysis of the cytotoxicity data 
obtained included calculation of hypoxia cytotoxicity ratios and selectivity ratios 
(Table 3.1). Hypoxic cytotoxicity ratio is defined the ratio of IC50 values under 
normoxia divided by IC50 values under hypoxia; a ratio greater than one means 
enhanced sensitivity under hypoxia a ratio of one means equipotent drug activity 
under aerobic and hypoxic conditions, and a ratio less than one means resistance 
under hypoxia; results are shown in table 3.1. DCA was active and appeared more 
sensitive to hypoxic HCT116 p53+/+, HCT116 p53-/-, HT29, BE and Panc10.05 
cancer cells with varied HCRs of 3.11, 1.43, 1.85, 1.84 and 1.86 respectively. Under 
aerobic conditions, DCA was only substantially more active against the LS123 
cancer cell than the ARPE19 non-cancer cells. However, as shown in Figure 3.6 and 
Table 3.1, DCA was more cytotoxic against all the cancer cell lines than the non-




















HCT116 p53-/- 20.09 ± 3.42 28.91 ± 1.81 1.43 1.83 
PANC 10.05 22.27 ± 3.30 41.62 ± 1.09 1.86 1.65 
HT-29 15.29 ± 2.53 28.34 ± 1.33 1.85 2.40 
HCT116 p53+/+ 7.15 ± 0.89 22.27 ± 0.58 3.11 5.15 
SW48 33.76 ± 3.84 45.23 ± 2.22  1.39 1.09 
BE 18.78 ± 2.40 34.66 ± 4.66 1.84 1.96 
LS123 27.40 ± 1.72 19.53 ± 0.94 0.71 1.34 
ARPE-19 79.46 ± 4.53 36.84 ± 7.52 0.46 N/A 
 
Table 3.1 Response of a panel of cancer and non-cancer (ARPE19) cells following 
continuous exposure to DCA under aerobic and hypoxic (0.1% oxygen) conditions. 
The HCR denotes hypoxic cytotoxicity ratio and this is defined as the IC50 in aerobic 
conditions divided by the IC50 under hypoxia. SR denotes the selectivity index which here 
represents the IC50 of ARPE19 cells in aerobic conditions divided by the IC50 for DCA under 


















Figure 3.6 Graphical representation of the response of cells to DCA. Each value represents the 
mean ± standard deviation for three independent experiments. DCA reduced cell growth of HCT116 
p53+/+ (**P <0.01), as well as reduce cell growth of HCT116, HT29, BE and PANC10.05 (*P<0.05) 
under hypoxic condition compare to aerobic condition. Black bar represents hypoxic cells; white bar 
represents normoxic cells. 
 
3.3.6 Response of colorectal cancer cells following short time exposure to 
DCA (1hour) under hypoxic and aerobic conditions.  
 The effect of DCA on HCT116 p53+/+, HCT116 p53-/-, HT-29 and BE cells following 
one-hour exposure is presented in figure 3.7. The response to DCA was varied 
between cell lines, but it was generally greater under hypoxic than the normoxic 
conditions. IC50 values under hypoxic conditions ranged from 173.9mM to 224.6mM 
whereas IC50 values under normoxic conditions ranged from 230.4 to >500mM. 
Given differences observed in the response to DCA between isogenic p53+/+ and 
p53-/- HCT116 cells, this suggested that p53 status could influence response which 











Figure 3.7 Response of HCT116 p53-/- (A), HCT116 p53+/+ (B), BE (C) and HT-29 (D) following a 
one-hour exposure to DCA under aerobic (blue) and hypoxic (red) conditions. Each value 











 IC50 Aerobic IC50 Hypoxic HCR 
HT-29 297.6 ± 22.2 173.9 ± 24.6 1.71 
BE >500 182.7 ± 4.83 >2.73 
HCT116 p53+/+ 359.5 ± 14.7 224.6 ± 25.3 1.60 
HCT116 p53-/- 230.4 ± 4.1 195.7 ± 18.2 1.17 
 
Table 3.2 Response of cell lines following a one-hour exposure to DCA under aerobic 
and hypoxic conditions. Each value represents the mean IC50 (mM) ± standard deviation 



















3.3.7 Influence of duration of drug exposure on the response of cells to DCA   
To investigate time dependent effects on the response of cells to DCA further 
experiments were conducted. The experiment compared the response of two 
colorectal cancer cell lines that have different p53 states HCT116 p53+/+ (p53 wild-
type) and HT29 (p53 mutated) using the MTT assay. Cells were treated with different 
concentrations of DCA between 0.976 and 500mM under 21% oxygen conditions 
(normoxia) incubated for different times (1hr, 2hr, 4hr, 6hr, 12hr, 24hr). It was found 
that DCA reduced cell viability in both cell lines (figure 3.8). There were minor 
difference in dose response between the two cell lines following DCA treatment at 
each time point but generally the pattern was similar. In both cases IC50 values 
decreased as the duration of drug exposure increases but analysis of concentration 
x time (C x T) parameters indicates a time dependent difference (Figure 3.8 E and 
F). Usually cell kill is proportional to the product of C x T but in this case, C x T 
parameters required to kill 50% of cells increased with time suggesting that DCA 



















          
 
Figure 3.8 Influence of drug exposure time on the response of HT29 (left-hand panels) and 
CT116 p53+/+ (right-hand panels) to DCA. Panels A and B present dose-response curves and 
panels C and D present the corresponding IC50 values (mean ± standard deviation for n = 3). Panels 












3.3.8 Determination of DCA stability by using HPLC analysis 
The main objective of this experiment was to test the stability of DCA in cell culture 
medium at 370C and 5% CO2 over time. For DCA measurements, standards of DCA 
solutions were prepared in cell culture medium (RPMI1460) with final concentrations 
ranging from 0.9765mM to 31.25mM. The results are presented in figure 3.9 with 
calibration curves and representative chromatograms presented in figure 3.10.  
In this case, no degradation of DCA dissolved in cell culture medium could be 
observed by HPLC measurement over a 24 hour period (figure 3.9). Quantitation 
using the DCA calibration curve was based on the peak area ratio. This was 
performed by using different concentrations (two-fold dilutions) of DCA dissolved in 
water and in RPMI 1640 medium, extraction using acetonitrile precipitation and 
analysis by HPLC analysis. Using this methodology, a peak of DCA was detected 
with retention at 10.600 min (figure 3.10). The chromatogram in figure 3.10 shows 
that separation of DCA that was achieved.  
The conclusion from this data is that there was no significant loss of DCA from 































Figure 3.9 Standard calibration curve to measure stability of DCA in medium at 37°C, 5% CO2 








































Figure 3.10 Calibration curve and representative chromatograms for the analysis of DCA. 
Panel A is a calibration curve using DCA dissolved in deionised water and panel B is a 
representative chromatogram of one of thee standards. A clear peak at 10.487 min is visible. 
Panles C to F represent chromatograms for media only (C) and DCA extracted from media 
at t=0 (D), t = 12 hours (E) and t = 24 hours (F). In all the cell culture media experiments, the 












3.3.9 Influence of different growth media on the response of HCT116 cells to 
DCA 
Figure 3.11 shows the influence of different cell culture media on the response of 
cells to DCA under hypoxic and normoxic conditions. HCT116 p53+/+ and HCT116 
p53-/- cells were cultured in complete DMEM and RPMI1640 media for 96 hours 
following a 1h exposure to DCA in these respective media. HCT116 p53+/+ cells that 
were cultured in DMEM and RPMI1640 media showed no significant difference in the 
response under aerobic conditions (IC50 359.5 ± 14.7 mM and 367.7 ± 57.1 mM 
respectively) In contrast under hypoxic conditions, HCT116 p53+/+ were more 
sensitive to DCA in RPMI1640 medium compared to DMEM with IC50 values of 180.7 
± 17.4 mM and 224.6 ± 25.3 Mm, respectively.  
The response of HCT116 p53-/- cells differed, with cells showing increased cytotoxic 
response to DCA in RPMI1640 medium compared to DMEM medium under aerobic 
conditions (IC50 values 196.3 ± 5.1mM and 230.4 ± 4.1 mM respectively) but not 
under hypoxic conditions (IC50 values 192.4 ± 7.2 mM and 195.7 ± 18.2 mM 
respectively; Table 3.3). It was shown that HCT116 p53+/+ cells are less sensitive to 
DCA in DMEM and RPMI1460 media under aerobic conditions compared to HCT116 
p53-/- (P-value <0.01) whereas under hypoxic conditions  both cell  showed similar 























Figure3. 2 Response of HCT116 p53+/+ and HCT116 p53-/- to DCA (1-hour exposure) in DMEM 
(panels A and B) and RPMI1640 (panel C and D) media. These experiments were conducted under 
both aerobic (blue) and hypoxic (red conditions) and each value represents the mean ± standard 












Cell line IC50 Aerobic 
(DMEM) 




IC50 Hypoxic  
(RPMI 1640) 
HCT116 p53+/+ 359.5 ± 14.7 367.7 ± 57.1  224.6 ± 25.3 180.7 ± 17.4 
HCT116 p53-/- 230.4 ± 4.1 196.3 ± 5.1 195.7 ± 18.2 192.4 ± 7.2 
 
Table 3.3 Response of HCT116 cells to DCA (1-hour exposure) under aerobic and 
hypoxic conditions in DMEM and RPMI 1640 culture media. Values presented are the 










Figure 3.12  IC50 values of HCT116 cells to DCA (1-hour exposure) under aerobic (left-hand panels) 
and hypoxic (right-hand panels)  conditions in DMEM and RPMI 1640 culture media (mean ± standard 
deviation for n = 3), black bar represents HCT116 p53+/+ cells; white bar represents 








3.3.10 Dose response of colorectal cancer cells to different glycolytic 
inhibitors under hypoxic and normoxic conditions. 
The effect of inhibitors of the glycolytic enzymes hexokinase II and LDH-A on cancer 
cell survival under normoxic and hypoxic conditions was also assessed.  Four 
colorectal cancer cell lines (BE, HT29, HCT116 p53+/+ and HCT116 p53-/-) were 
investigated; two hexokinase II inhibitors, 2-Deoxy-D-glucose (2DG) and 3-
Bromopyruvic acid (3BP) were compared under hypoxic and normoxic conditions. 
2DG had similar cytotoxic effects under both conditions. For normoxic conditions 
IC50 values ranged between 1.09 and 1.65 mM whereas for hypoxic conditions the 
IC50 values ranged between 0.99 mM and 2.43 mM.(summarised in table 3.4).  In 
contrast, 3BP showed different effects between cells under normoxic compared to 
hypoxic conditions.  3BP was consistently less active towards the cancer  cells 
grown under hypoxic conditions( figure 3.13, 3.16 and table 3.4). Hypoxia cytotoxicity 
ratios ranged from 0.34-0.67 consistent with reduced activity towards hypoxic cells. 
All four cell lines had similar responses to gossypol and sodium oxamate. Both of 
these LDH-A inhibitors were consistently less active against all 4 cancer cell lines 
under hypoxic conditions compared to activity under aerobic conditions (Figure 3.13, 
3.16 and summarised in table 3.4). It was also apparent that the BE cell line was 
more resistant in general to several of the inhibitors under both conditions; this was 
particularly so for 3BP (Table 3.4). Hexokinase and lactate dehydrogenase inhibitors 
have shown less effective in hypoxia conditions to colorectal cancer cells compared 










Figure 3.3 Response of HCT116 p53+/+ cells to 2-deoxy-glucose (2-DG), 3-bromopyruvate (3-
BP), sodium oxamate and gossypol under aerobic (blue) and hypoxic (red) conditions. The 
duration of drug exposure was 96 hours, and each value represents the mean ± standard deviation 

































Figure 3.4 Response of HT-29 cells to 2-deoxy-glucose (2-DG), 3-bromopyruvate (3-BP), 
sodium oxamate and gossypol under aerobic (blue) and hypoxic (red) conditions. The duration 
of drug exposure was 96 hours, and each value represents the mean ± standard deviation for three 

















Figure 3.5 Response of HCT116 p53-/- cells to 2-deoxy-glucose (2-DG), 3-bromopyruvate (3-BP), 
sodium oxamate and gossypol under aerobic (blue) and hypoxic (red) conditions. The duration 
of drug exposure was 96 hours and each value represents the mean ± standard deviation for three 


















Figure 3.6 Response of BE cells to 2-deoxy-glucose (2-DG), 3-bromopyruvate (3-BP), sodium 
oxamate and gossypol under aerobic (blue) and hypoxic (red) conditions. The duration of drug 
exposure was 96 hours, and each value represents the mean ± standard deviation for three 








  IC50 ± standard deviation (n = 3) 




Aerobic 1.65 ± 0.38 1.45 ± 0.17 1.26 ± 0.29 1.09 ± 0.21 
Hypoxic 2.43 ± 2.53  0.99 ± 0.36 1.38 ± 0.43 1.46 ± 0.39 




Aerobic 29.9 ± 3.6 134.1 ± 18.7 27.8 ± 4.6 27.5 ± 4.8 
Hypoxic 66.5 ± 11.4 212.9 ± 57.6 54.2 ± 15.5 55.5 ± 13.1 




Aerobic 3.28 ± 1.22 5.68 ± 0.76 2.15 ± 0.61 2.07 ± 0.59 
Hypoxic 5.12 ± 0.63 13.3 ± 0.4 4.09 ± 1.07 4.98 ± 2.10 





Aerobic 49.8 ± 20.8 62.2 ± 17.6 49.2 ± 16.1 52.7 ± 17.0 
Hypoxic 71.8 ± 22.6 79.4 ± 39.3 60.4 ± 13.2 60.1 ± 18.2 
HCR 0.69 0.78 0.81 0.87 
 
Table 3.4 Response of a panel of cells lines to glycolytic inhibitors under aerobic and 
hypoxic conditions (continuous 96-hour drug exposure). Each value represents the 
mean IC50 ± standard deviation for three independent experiments. HCR denote the hypoxic 
cytotoxicity ratio define as the IC50 under aerobic conditions divided by the IC50 under 

























Figure 3.17 Summary of Hypoxia Cytotoxicity Ratios (HCRs) for tested glycolytic inhibitors. 
Panel A Hexokinase inhibitors and panel B lactate dehydrogenase inhibitors HCR value > 1 indicate 












Figure 3.18 summarises the differences in response obtained under hypoxia and 
normoxia for each of different metabolic inhibitors tested. The key question being 
addressed in this chapter was whether any of these metabolic inhibitors might serve 
as hypoxia selective agents. As can be seen from this figure, unexpectedly, with the 
exception of DCA, none of the other inhibitors showed preferential activity against 

























Figure 3.7 Summary of all the HCR data generated using a panel of glycolytic inhibitors and 
cell lines. The Y-axis is set at a HCR of 1 on the X-axis, and this represents equal activity against 
aerobic and hypoxic cells. HCR value > 1 indicate selectivity for hypoxic cells whereas HCR values < 
1 indicate resistance under hypoxia. As the HCR values are calculated from the mean IC50 values, 








3.3.11 Dose response of ovarian cancer cells to AKT inhibitors under hypoxic 
and normoxic conditions. 
The response of IGROV cells, a human ovarian cancer cell line provided by Dr. 
Paola Perego (National Cancer Institute / Italy) to novel Akt inhibitors PP-1, PP-2 
and PP-3 was investigated  (figure3.19). IGROV cells were selected in order to align 
with previous studies performed by Dr.Perego. The effects of these compounds on 
IGROV cells under both normoxic and hypoxic conditions were determined. Dose 
response curves are presented in figure 3.20. The cells did not respond to PP-3 with 
IC50 values greater than 30μM under both aerobic and hypoxic conditions. Whilst no 
IC50 values were obtained with PP-1, there was evidence of activity with survival 
values close to 50% at the highest concentration tested. There was no evidence of 
differential PP-1 activity between aerobic and hypoxic conditions. The most active 
compound was PP-2 with IC50 values under hypoxic and aerobic conditions of 23.38 
± 3.25 and 21.57 ± 2.73 respectively. The difference between the two groups was 































































Purity = 95% by NMR
Purity >95% by NMR




amount : about 2,0 mg
amount : about 2,5 mg
amount : about 2,9 mg
 












Figure3. 20 Response of IGROV cells to PP-1 to PP-3 under aerobic (blue) and hypoxic (red) 
conditions. Dose-response curves are presented in the three graphs, and each value represents the 
mean ± standard deviation for three independent experiments. The inset table represents IC50 values 
for all experimental conditions. IC50 values >30 indicate that an IC50 was not reached at the highest 















PP-1 > 30 >30 
PP-2 23.4 ± 2.6 21.6 ± 2.2 












3.3.12 Western blot analysis of cellular PDH phosphorylation levels in 
response to DCA treatment  
Of the metabolic inhibitors investigated in this chapter, the PDK inhibitor DCA was 
the only inhibitor that showed any preferential activity towards hypoxic cells (Figure 
3.18) and was therefore selected for further evaluation. DCA was presumed to have 
its cytotoxic effects via inhibition of PDKs. As discussed in section 1.12   PDKs 
phosphorylate and inactivate pyruvate dehydrogenase (PDH), thus it was predicted 
that DCA might cause a decrease in levels of phosphorylated PDH. This in turn 
would be expected to promote entry of pyruvate into the TCA cycle/OXPHOS rather 
than its reduction by LDH-A to lactate. Effects of DCA on PDH phosphorylation and 
PDK expression levels were therefore analysed by immunoblotting following SDS 
PAGE of total cell lysates. 
3.3.12.1 Bradford assay calibration curve  
For these analyses, correlating with IC50 values for 96h exposure obtained by 
chemosensitivity testing, HCT116 p53+ /+ and HCT116 p53-/- cells were exposed to a 
range of DCA concentrations (0mM, 5mM, 10mM and 20mM) for 72 hours in the 
defined environment (aerobic or hypoxic conditions). Following treatment, the 
expression levels of PDK1, PDK2, PDH-P and PDH protein were measured by 
western blot analysis of HCT116 p53+ / + and HCT116 p53-/- cells. In each case, 30µg 
of protein from prepared cell lysates (see Methods) were applied to each lane of a 
SDS-polyacrylamide gel. Protein concentrations of cell lysates were determined 



















Figure 3.21 Bradford calibration curve that was used to determine the concentration of cell lysates.  
3.3.12.2 Immunoblots 
Immunoblotting results are presented in Figure 3.22, 3.23 and 3.24. The results 
show that the level of PDH expression does not significantly change with DCA 
treatment across the different doses tested although there is some variation between 
normoxic and hypoxic samples. PDH total expression serves as a comparative 
control in assessing PDH phosphorylation levels, Importantly, DCA induced a 
decrease in PDH phosphorylation relative to total PDH levels in both HCT116 p53+/+ 








absence of any DCA treatment, PDH phosphorylation levels were notably higher 
than under aerobic conditions suggesting increased inactivation of the PDH complex, 
potentially by PDK-1. In the HCT116 p53+/+ cells, DCA also caused a dose-
dependent reduction in PDH phosphorylation levels consistent with PDK inhibition by 
DCA. However, in the HCT116 p53-/- cells, DCA treatment at the doses tested did 
not reduce PDH phosphorylation levels (figure 3.22 and 3.23).This could potentially 
be due to alterations in expression or activity of PDKs or PDH phosphatases as a 
compensatory response to DCA. In addition, the blots indicate that levels of PDK2 
expression were particularly hard to detect in both cell lines under all conditions due 
to interfering non specific bands. With additional time available, this study would 
have included measuring the enzyme activity of PDK1 and other PDK isoforms 




































Figure 3.22 Western blot analysis of HCT116 p53+/+ cells treated with different dose of DCA 
under hypoxic and aerobic conditions for 72 hours. An exposure time of 72 hours was chosen as 
extending the time point beyond this time point would induce significant cell kill and a reduction of 
protein available for analysis. (A) Western blot analysis of PDH-P expression. (B) Western blot 
measure expression of PDK1. (C) Western blot measure expression of PDH. (D) Western blot 


















    
Figure3. 23 Western blot analysis of HCT116 p53-/- cells treated with a different dose of DCA 
under hypoxic and aerobic conditions for 72 hours. An exposure time of 72 hours was chosen as 
extending the time point beyond this time point would induce significant cell kill and a reduction of 
protein available for analysis (A) Western blot analysis of PDH-P expression. (B) Western blot 
measure expression of PDK1 (C) Western blot analysis of PDH protein expression (D) Western blot 












































Figure 3.24 Western blot analysis of β-actin of treated cells with a different dose of DCA under 
hypoxic and aerobic conditions for 72 hours. Panel (A) represents HCT116 p53+/+ cells and panel 
(B) represents HCT116 p53-/- cells.  
(A) 
(B) 
β- actin (43kDa) 








3.3.13 Measurement of cell viability and mitochondrial membrane potential of 
cells treated with DCA under hypoxic and aerobic conditions.  
To investigate further the chemosensitivity of cell lines to DCA, quantification of 
effects on cell viability and total cell number and on loss of mitochondrial membrane 
potential as an early marker of apoptosis were carried out. These assays were 
performed on HCT116 p53+/+ and HT29 cells with varying concentrations of DCA 
under hypoxic and normoxic conditions.  Loss of mitochondrial membrane potential 
was assessed using J-aggregate-forming cation JC-1 and analysis of JC1 red/green 
fluorescence by image cytometry. DCA was shown to induce mitochondrial 
membrane depolarisation with increased loss of mitochondrial membrane potential 
observed in both the HCT116 and HT29 cells under hypoxic conditions using a dose 
of 62.5mM DCA. (Figure 3.25. & 3.26 for HCT116 p53+/+; Figure 3.28 and 3.29 for 
HT29). DCA also caused a decrease in total cell numbers and percentage of cell 


































Figure 3.25 Mitochondrial potential membrane of HCT116 p53+/+ cells treated with a range of 
DCA concentrations under aerobic conditions for 72 hours. Panel A untreated cells (control), 
panel B cells treated with 15.63mM of DCA. Panel C cells treated with 31.255 mM of DCA and Panel 
D cells treated with 62.5 mM of DCA. Cells in the lower right quadrant represent cells with depolarised 
mitochondria as indicated by a decrease in the red/green fluorescent intensity ratio 
(A)   Control (B)  15.63mM DCA  






























Figure 3.8 Mitochondrial potential membrane of HCT116 p53+/+ cells treated with a range of 
DCA concentrations under hypoxic conditions for 72hours. Panel A untreated cells (control), 
panel B cells treated with 15.63Mm of DCA. Panel C cells treated with 31.255mM of DCA and Panel 
D cells treated with 62.5 mM of DCA. Cells in the lower right quadrant represent cells with depolarised 
mitochondria as indicated by a decrease in the red/green fluorescent intensity ratio.  
(A)   Control (B)  15.63mM DCA  

























Figure 3.9 Summary of the effects of DCA on mitochondrial potential membrane, cell number 
and cell viability of HCT116 p53+/+ cells treated under aerobic and hypoxic conditions for 
72hours. Panel A: Percentage of apoptotic cells under aerobic and hypoxic conditions as determined 
by measurement of loss of mitochondrial membrane potential, panel B: The total number of live and 
dead cells following 72h DCA treatment under aerobic conditions;  ,and Panel C The total number of 
live and dead cells following 72h DCA treatment under hypoxic conditions panel D: Percentage cell 






































Figure 3.10 Mitochondrial potential membrane of HT29 cells treated with a range of DCA 
concentrations under aerobic conditions for 72 hours. Panel A is untreated cells (control), panel 
B cells treated with 15.63mM of DCA. Panel C cells treated with 31.25mM of DCA and Panel D cells 
treated with 62.5mM of DCA.  
(D) 62.5mM DCA  (C) 31.25mM DCA  
































Figure 3.11 Mitochondrial potential membrane of HT29 cells treated with a range of DCA 
concentrations under hypoxic conditions for 72 hours. Panel A is untreated cells (control), panel 
B cells treated with 15.63mM of DCA. Panel C cells treated with 31.25mM of DCA and Panel D cells 
treated with 62.5mM of DCA.  
 
(D) 62.5mM DCA  (C) 31.25mM DCA  






















Figure3. 30 Summary of the effects of DCA on the mitochondrial potential membrane, cell 
number and cell viability of HT29 cells treated under aerobic and hypoxic conditions for 
72hours. Panel A apoptosis levels under aerobic and hypoxic conditions as determined by loss of 
mitochondrial membrane potential, panel B total of live and dead cells under hypoxic conditions, panel 
C is total of live vs dead cells under aerobic condition, and Panel D percentage cell viability under 












3.3.14 Comparison of the effects of different DCA treatment durations on 
mitochondrial potential membrane and cell viability  of HCT116 cells under 
normoxic conditions  
HCT116 p53+/+ (wild-type) cells were treated with 75mM DCA under 21% oxygen 
conditions (normoxia) for different times (24hr, 36hr, 48hr, 60hr, 72hr). DCA caused 
an increase in mitochondrial membrane depolarisation in a time-dependent manner 
suggesting induction of early apoptosis with time (Figure 3.31 and 3.32). Consistent 
with cells being in the early stages of apoptosis, effects on cell viability were much 












































Figure 3.31 Mitochondrial membrane potential of HCT116 p53+/+ cells exposed 75mM DCA for 
different time periods under aerobic conditions. Panel A.1 And A.2 is 24 hours dose exposure. 
Panel B.1 and B.2 cells treated for 36 hours. Panel C.1 control and C.2 cells treated for 48hours. 
(A.1) Control (24hr) (C.1) Control (48hr) (B.1) Control (36hr) 
(C.2) 75mM DCA 
(48hr) 
(A.2) 75mM DCA 
(24hr) 

































Figure 3.32 Mitochondrial membrane potential of HCTt116 p53+/+ cells exposed to 75mM DCA 
for different time periods under aerobic conditions. Panel A.1 And A.2 is 60 hours dose exposure. 
Panel B.1 and B.2 cells treated for 72hours.  
(A.1) Control (60hr) 
(A.2) Control (72hr) 
(B.1) 75mM DCA 
(60hr) 






























Figure 3.33 Mitochondrial membrane potential and viability of HCT116 p53+/+ cells exposed to 
75mM DCA for different time points under aerobic conditions. Panel A is presenting the 











3.4 Discussion  
Many independent studies highlight the important metabolic alterations of cancer 
cells and this is now recognised as an emerging hallmark of cancer (Hanahan and 
Weinberg 2011). This biological understanding provides novel opportunities for 
therapeutic intervention, particularly in the hypoxic fraction of tumours where the 
glycolytic phenotype may be even more prominent than in aerobic cells. This study 
focused on the comparative response of the cancer cells to glycolytic inhibitors 
(hexokinase and lactate dehydrogenase inhibitors) and the PDK inhibitor DCA under 
hypoxic and normoxic conditions. Whilst our results with tirapazamine demonstrate 
that our experimental conditions are suitable for evaluating hypoxia targeted drugs, 
the results obtained using 2DG or 3BP (hexokinase inhibitors), DCA (pyruvate 
dehydrogenase kinase inhibitor), gossypol and sodium oxamate (LDH inhibitors) 
show limited effects on hypoxic cells and in many cases, hypoxic cells proved more 
resistant to treatment than aerobic cells. The potential reasons for each of the key 
sets of results obtained are discussed below.  
First, the results obtained for DCA did show a degree of hypoxia selectivity although 
the magnitide of the HCR was much lower (HCR ranged from 3.11 to 0.71, table 3.1) 
than that obtained for tirapazamine (HCR = 9.63, figure 3.3). Furthermore, HCR 
values varied depending on the cell line with only LS123 cancer cells had an HCR 
value below 1 (HCR=0.71, table 3.1). These modest effects are consistent with other 
studies showing little or no potentiation under hypoxia (0.5% oxygen) in MCF7 and 
MDA-MB-231 breast cancer cell lines (Xintaropoulou et al 2015). Other studies have 








the survival of an aggresive hypoxic cell population (Anderson et al, 2009). Similarly, 
Shahrzad et al (2010) demonstrated that SW480 and CaCo-2 cells were less 
sensitive to DCA under hypoxic compared to normoxic conditions and concluded that 
DCA may in fact be cytoprotective to some colorectalc cancer cell lines under 
hypoxic conditions (0.1% oxygen). The results presented in this thesis together with 
evidence in the literature suggests that DCA may demonstrate modest hypoxia 
selectivity in some cell lines but in others, little or no hypoxia selectivity occurs and in 
some cases, a protective effect against hypoxic cancer cells was observed.  
Mechanistically, DCA is known to inhibit the enzyme pyruvate dehydrogenase kinase 
(PDK) which plays a key role in regulating the pyruvate dehydrogenase (PDH) 
complex thereby controlling the entry of pyruvate into the Kerbs cycle (Michelakis et 
al, 2008, Bonnet et al, 2007). PDK phosphorylates the PDH complex at specific 
serine residues resulting in inhibition of enzyme activity (Rardin et al 2009). Using 
antibodies to the PDH E1 (phospho S293), immunoblot studies showed modest 
inhibition of PDH phosphorylation under normoxic conditions following the treatment 
of HCT116p53+/+ and HCT116p53-/- cells with DCA for 72 hours (figures 3.22A and 
3.23A respectively). Under hypoxic conditions, PDH-P expression was elevated in 
control cultures which would be consistent with a HIF1 mediated induction of PDK1. 
Whilst a very modest induction of PDK1 levels occurred in HCT116p53-/- cells (figure 
3.23B), no noticable change in expression occurred in HCT116p53+/+ cells (figures 
3.22B). It should be noted however that the results of the immunoblot studies are 
preliminary and need to be repeated before any firm conclusions can be reached. 








under hypoxic conditions although the effect is modest and is not qualitatively 
different from the results of studies in oxygenated conditions. As DCA has been 
shown to alter mitochondrial membrane potential and induce apoptosis (Michelakis 
et al, 2009, Bonnet et al, 2007), further mechanistic studies were conducted to 
determine the effects of DCA on mitochondrial membrane depolarisation under 
aerobic and hypoxic conditions (figures 3.27A, 3.30A and 3.33A). The results 
demonstrate that DCA does induce mitochondrial membrane depolarisation which is 
consistent with previously published studies (Bonnet et al, 2007). Under hypoxic 
conditions, the extent of membrane depolarisation was similar to aerobic conditions 
except at a dose of 62.5 mM where greater depolarisation occurred. This 
concentration of DCA is high however and at therapeutically relevant concentrations 
(IC50 values range from 7.15 to 33.76 mM, table 3.1), no major differences in 
mitochondrial membrane potential exist between hypoxic and aerobic cells. These 
results are preliminary in nature and further replicates are required to confirm these 
findings.  
In summary, DCA has shown some modest hypoxia selectivity in a panel of cancer 
cell lines but the magnitude of this effect is small and cell line dependent. 
Mechanistically, these preliminary studies demonstrate that DCA reduces PDH-P 
levels and alters mitochondrial membrane potential but the effects are similar under 
both aerobic and hypoxic conditions (at therapeutically relevant DCA 
concentrations). In conjunction with the evidence in the literature, the enhanced 








Turning to the other glycolytic inhibitors used in this study, hexokinase inhibitors (2-
deoxyglucose and 3-bromopyruvate) were generally less active against hypoxic cells 
compared to aerobic cells (table 3.4). The only exception to this was in the case of 
the BE cell line where a modest HCR of 1.46 was obtained. These results are 
consistent with other studies demonstrating that hypoxic cells were significantly less 
sensitive to 3-bromopyruvate than aerobic cells (Xintaropoulou et al 2015) but 
conflict with others demonstrating that osteosarcoma 143b cells were hypersensitive 
to 2-deoxyglucose under hypoxic conditions (Maher et al 2004). The results obtained 
with 2-deoxyglucose were however consistent with other studies demonstrating that 
hypoxia protects glioblastoma cells from the apoptotic effects of 2-deoxyglucose 
(Pistollato et al, 2010). With regards to inhibitors of LDH, both gossypol and sodium 
oxamate were significantly less active against hypoxic cells compared to aerobic 
cells with HCR values ranging from 0.41 to 0.87 (table 3.4). These results are 
consistent with similar studies conducted using oxamate in MCF7 and MDA-MB-231 
cells where hypoxic cells (0.5% oxygen) were significantly less responsive that 
aerobic cells (Xintaropoulou et al 2015). In this same study, similar results were 
obtained with another LDH inhibitor (NHI1). Limited studies have been published on 
the response of hypoxic cells to gossypol but the results of this study clearly 
demonstrate that gossypol is less active against hypoxic compared to aerobic cells. 
Other inhibitors of LDH-A have however been shown to have significant hypoxia 
selectivity in vitro. In contrast to the results from Xintaropoulou et al (2015), NHI1 
was significantly more active against hypoxic LPC006 pancreatic cancer cells 








be selectively toxic to hypoxic cells, the magnitude of the effect being greater in cell 
lines that expressed low levels of LDH-B (Billiard et al, 2013).  
In summary therefore, the glycolytic inhibitors used in this study did not exhibit 
selectivity towards hypoxic cells and in just about all cases, they were less active. 
Evidence in the literature however suggest that targeting LDH-A can generate 
hypoxia selective effects in certain cell lines. The reasons for the discrepancies 
between the results of this study and evidence in the literature are  not clear but 
could be cell line or inhibitor specific. Gossypol and sodium oxamate for example are 
not specific inhibitors of LDH-A and may have multiple mechanisms of action 
whereas other inhibitors with greater selectivity for LDH-A may elicit hypoxia 
selective effects in vitro. It is of interest to note however that the magnitude of any 
hypoxia selectivity effects induced by glycolytic inhibitors and DCA is typically small 
and this raises intriguing questions; are hypoxic cells really glucose dependent and 
can hypoxic cells use alternative sources of carbon as metabolic fuels? These 















Investigation into alternative carbon sources as metabolic fuels to support 
cancer cell growth under hypoxic conditions.  
4.1 Introduction 
Cancer cells have very high energy and biosynthetic needs that are required to 
support their rapid cell growth and proliferation. To provide sufficient energy and 
biosynthetic precursors for synthesis of cellular macromolecules, cancer cells 
commonly reprogram their metabolism towards glycolysis. This phenomenon 
contributes to high glucose import (via glucose transporters) into the cells and high 
glucose consumption (via upregulation of glycolytic enzymes) to generate ATP 
(Fadaka et al., 2017). However, glucose deprivation and lactic acidosis are a 
common feature in hypoxic cells that arise in areas of the tumour microenvironment 
further away from blood vessels which therefore do not receive sufficient oxygen or 
glucose.  In the context of the tumour microenvironment, a metabolic symbiotic 
model has been proposed by Sonveaux and colleagues where ’metabolic coupling’ 
between ‘oxidative’ tumour cells near to blood vessels and hypoxic cancer cells 
occurs. In this model, the hypoxic cells metabolise glucose to lactate which is then 
exported and used as an fuel by ‘oxidative’ tumour cells near blood vessels reducing 
their consumption of glucose. These metabolic interactions are similar to the 
“reverse Warburg effect” concept developed by Lisanti et al (Fu et al., 2017) where 
normal cells are ‘told’ by tumour cells to produce lactate which is then used as a fuel 








cancer cells is glutamine action (Reitzer et al., 1979). Whilst use of glucose and 
glutamine as carbon sources by cancer cells is well established, potential differences 
in dependency between normoxic and hypoxic cells and the use of alternative 
carbon sources to support cancer cell survival have yet to be extensively studied. In 
case of insufficient of glucose, in which the energy is produced by glycolysis. Data 
show that tumour cells possible can use for example mannose and survive under 
severe condition up to concentration limit 2.5mM. Mannose plays an important role in 
the metabolism of many cancer cells, it is mainly essential for glycoprotein 
biosynthesis (glycosylation). In this way, mannose promotes the proliferation of 
cancer cells. This is particularly relevant for hypoxic cells and may highlight novel 
therapeutic strategies for their targeting.   
4.2 Materials and Methods 
4.2.1 Cell culture 
Investigation of the effects of glucose deprivation on cell survival under aerobic and 
hypoxic conditions was conducted using the MTT assay and verified using the SRB 
assay.  The panel of cell lines used included HCT116 p53-/-, HCT116 p53+/+, HT29, 
BE and DLD1 cells, all of which were derived from colorectal tumours. Normal cell 
culture media for these cells were as follows: HCT116 p53-/- and HCT116 p53+/+ cells 
were cultured in DMEM media containing 20mM glucose supplemented with 10% 
FBS, 2mM L-glutamine and 1mM of sodium pyruvate. HT29, BE and DLD1 were 
cultured with RPMI1640 media containing 20mM glucose supplemented with 10% 








cancers, the pancreatic cancer cell line (PSN1) cell was also used and this was 
cultured in RPMI1460 media supplemented with 10% FBS and 2mM L-glutamine 
and 1mM of sodium pyruvate. The non-cancer cell line ARPE 19 cell was cultured in 
DMEM/ F12 media supplemented with 10% FBS and 2mM L-glutamine. Cells were 
maintained under standard cell culture conditions in a humidified atmosphere 
containing 5% CO2 and 37C.  
4.2.2 Influence of glucose deprivation on cell growth  
Influence of glucose deprivation on cell survival was evaluated using a range of 
glucose concentrations and under different oxygen tensions. Cells were seeded in 
96 well plates at 2 x 103 cells per well and following an overnight incubation in 
normal glucose rich media and aerobic conditions (to allow cells to adhere and 
recover from trypsinisation), cells were transferred to the hypoxystation and the 
media replaced with glucose deprived culture medium that had been allowed to 
equilibrate overnight at 0.1% oxygen. Initially, HCT116 p53+/+ and HCT116 p53-/- 
cells were exposed to glucose free media (DMEM without glucose), supplemented 
with 10% FBS, L-glutamine (2mM) and sodium pyruvate (1mM) for 96 hours in a 
humidified atmosphere containing 0.1% oxygen. Following 96 hours, cell viability 
was determined using the MTT assay. To determine the effect of different glucose 
concentrations on cell survival, glucose (Sigma-Aldrich, G8270) was added to culture 
medium to give a concentrations ranging from 0.625mM to 20mM. These 
experiments were carried out at 0.1%, 1% and 5% oxygen in the hypoxia chamber 








4.2.3 The recovery of cells following glucose deprivation under aerobic and 
hypoxic conditions   
To determine whether cells are able to recover following a period of glucose 
deprivation, glucose rich media was added to cultures following a 96 hour incubation 
in glucose deprived media. Following the addition of glucose rich media, cells were 
cultured for a further 48 hours and cell survival determined using the MTT assay as 
described previously. The same cell line panel was employed as in section 4.2.2 and 
experiments were conducted under atmospheric and hypoxic (0.1% oxygen) 
conditions.  
4.2.4 Validation of the results obtained using the MTT assay using the 
sulforhodamine B (SRB) assay. 
Because the MTT assay measures mitochondrial function that could be influenced 
significantly by changes in glucose concentration and oxygen tension, the SRB 
assay was used to confirm whether or not the results generated by the MTT assay 
are valid. The SRB assay is a colorimetric test based on the determination of the 
amount of cellular protein content as an indicator of viable cell number. 
Sulforhodamine B is an anionic dye that binds to cellular proteins. Fixed cells are 
SRB-stained which is then solubilized by a basic solution (10mM Tris) in order to be 
measured optically. Thus, the optical density is a measure of total protein 
concentration and this is proportional to the number of living cells.  
Cells were cultured into 96 well plates at 2000 cells per well, after 24 hours media 








from 0mM to 20mM). Cells were incubated at aerobic and hypoxic conditions for 96 
hours. Cells were fixed with 10% (w/v) TCA buffer (100µl was added per well). Plates 
were incubated at 4C˚ for 1 hour following which fixed cells were washed 4 times 
with deionised water in order to remove the fixing buffer. Plates were dried for up to 
2 days on the bench. Fixed cells were then stained with 0.057% (w/v) of 
sulforhodamine B (SRB) (dissolved in 1% (v/v) acetic acid) for 30 minutes at room 
temperature.  After this, stained cells were washed 4 times with 1% acetic acid in 
order to remove unbound stain. Protein dye was solubilized with 10mM Tris-base 
(200 µl was added per each well). The optical density was measured by using a 
Tecan f500 plate reader at 590nm.  
4.2.5 Analysis of alternative carbon sources to glucose  
Tumour cells were exposed to glucose deprived media supplemented with a series 
of alternative carbon sources. These included the most common monosaccharides 
fructose (F3510), D-galactose (G5388) and D-mannose (M6020) and the 
disaccharide sucrose (S8501). In addition, sodium lactate (L7022) was included as 
this is known to be exported from cells undergoing aerobic glycolysis and it is likely 
to be at high concentrations in poorly perfused regions of tumours. In addition, 
lactate is able to fuel mitochondrial respiration through its conversion to pyruvate by 
LDH-B. All sugars were obtained from Sigma-Aldrich and the information in 
parenthesis represent the catalogue numbers. Cells were exposed to supplemented 
media for 96 hours in aerobic and hypoxic conditions and cell survival was 
determined using the MTT assay as described above. In addition, images of cells 








Fisher Scientific).  
4.2.6 Western blot analysis of mannose 6 phosphate isomerase and mannose 
monophosphate. 
HCT116 p53-/- and HCT116 p53+/+ cells were cultured in T25 flasks at 2.75x105 
cells/flask with high glucose media under aerobic and hypoxic condition. After 24 
hours, high glucose media was replaced with free glucose media enriched with 
10mM mannose (control cells contained high glucose media only). Cells were 
incubated for 96 hours under aerobic and hypoxic (0.1% oxygen) following that they 
were lysed in RIPA buffer for 10 minutes on ice. The lysed cells were sonicated and 
stored at -20C. Protein concentrations were determined using the BCA assay 
(described earlier in section 3.3.10) and samples (30μg) were separated on 15% 
SDS-PAGE gel and proteins transferred to nitrocellulose membrane as described 
elsewhere (see section 2.8.4). Membranes was blocked with 5% TBS-T milk buffer 
and probed with primary antibody for mannose-6 phosphate isomerase (P6MI), 
phosphomannomutase 2 (PMM2) and β-Actin overnight at 4 ° C. The appropriate 
secondary antibody recognizes the protein of interest and this was incubated with 
the blot for 1 hour at room temperature. The membrane was visualized using the LI-
COR fluorescent imaging. Details of all antibodies used are presented in section 
2.8.5 of this thesis.  
4.2.7 Influence of glutamine on the survival of cells under aerobic and hypoxic 
conditions.  








hypoxia, the effect of glucose deprivation with and without glutamine was determined 
under both aerobic and hypoxic conditions. The experimental design is similar to that 
described above and specific experimental conditions are described in the legends 
to relevant figures in the results section.  
4.2.8 The effect of 2DG and 968 on the survival of cells under aerobic and 
hypoxic conditions.  
Based on the results obtained in the previous experiment, glutamine can be used as 
a fuel to promote the survival of cells in glucose deprived conditions under aerobic 
conditions. This suggests that the use of a glycolytic inhibitor (such as 2DG) in 
combination with a glutaminase inhibitor (such as 968) could work together to 
eradicate aerobic cells under glucose rich conditions. The studies described below 
were designed to determine the effects of 2DG and 968 on aerobic cells in glucose 
rich medium prior to using them in combination (due to time constraints however, 
combination studies were not performed). The effects of 2DG on cell survival under 
hypoxic and aerobic conditions has been described in the previous chapter (figure 
3.12 to 3.16) but in order to obtain a direct comparison on the same batch of cells, 
the 2DG experiments were repeated and done at the same time as the 986 
experiments. In addition to studies being conducted under aerobic conditions, 
parallel studies under hypoxic conditions were performed as a comparison.  
Cell survival of HCT116 p53+/+ and HCT116 p53-/- cells following continuous 
exposure to 2DG (glycolytic inhibitor) and 968 (glutaminase inhibitor; TOCRIS; 








flat bottom plates at a final concentration of 2000 cells per well in appropriate culture 
medium. For studies conducted under normoxia, plates were incubated under 
standard conditions of 37 °C in humidified air with 5% CO2. For hypoxic conditions, 
plates were incubated in a H35 HypOxystation (Don Whitley Scientific, Shipley, UK) 
which provides a stable atmosphere of humidified gases consisting of 5% CO2, 0.1% 
oxygen with the remainder made up with nitrogen. The chamber is also heated to 
maintain a temperature of 37oC. In both cases, cells were seeded into 96well plates 
and incubated under normoxic or hypoxic conditions for 24 hours prior to drug 
exposure. 
Following 24-hours incubation, medium was removed from each well and replaced 
with high glucose medium and glucose free medium contained various 
concentrations of inhibitor.  Details of the inhibitors used and their preparation is 
presented in table 2.1. Plates were set up for each compound as described in 
chapter two (section 2.6.2). Plates were incubated at 37oC for 96 hours before cell 
survival was assessed using the MTT assay. As described in chapter two, 20µl of 
5mg/ml MTT solution was added to each well and allowed to incubate for 4hours in 
the incubator at 5% CO2 and 37°C. The cells were processed as described above 
and cell survival was determined by dividing the true absorbance of the treated wells 
by the true absorbance of the controls (expressed as a percentage). Cell survival 
was plotted against drug concentration to generate a dose response curve and the 
IC50 (concentration required to kill 50% of cells) was determined for each cell line 
and treatment. Due to time constraints, combination studies were not performed but 








4.2.9 Measuring glucose level in cell culture medium  
Glucose levels were measured in high glucose medium (supplemented with 10% 
FBS, 1mM, 2mM l-glutamine) and Free glucose medium (supplemented with 10% 
FBS, 1mM, 2mM l-glutamine) using the Rofloton chamber (Roche). A 32µL sample 
of medium was loaded onto the magnetic strip and immediately measured by 
Rofloton chamber according to the manufacturer’s instructions (Roche).  
 
4.3 Results  
4.3.1 Influence of glucose deprivation on cell growth under aerobic and 
hypoxic conditions.  
The effect of glucose deprivation on the survival of a panel of cancer cell lines under 
aerobic and hypoxic conditions are presented in figure 4.1 to 4.6. For all six cell 
lines, glucose deprivation was generally well tolerated for cells grown under aerobic 
conditions. For many of the cell lines (HCT116 p53+/+ and p53-/-, HT29, DLD1) 
depletion of glucose to levels 0.625mM only modestly reduced cell survival. For 
these cell lines, even in the complete absence of glucose, survival levels remained 
high (for example for HCT116 p53+/+ and DLD1, survival >75%). The most significant 
drop in survival under aerobic conditions occurred in HT-29 (figure 4.3) and BE 
(figure 4.4) cells where cell survival fell to ~40% compared to the control in the 
absence of glucose in the media.  








all cell lines. This was associated with notable morphological changes in the 
appearance of cells under phase contrast microscopy. The most significant effects 
were observed in the HCT116 p53+/+ cell line (figure 4.1) with cell survival values 
typically ~10% of that of controls. For HCT116 p53-/-, HT29, BE and PSN1 cell lines, 
survival under hypoxia in the absence of glucose was ~15-20%. The use of media 
with of different concentrations of glucose revealed dose dependent effects of 
glucose deprivation on cell survival under hypoxia with effects of specific 
concentrations being cell line dependent. In the case of HCT116 p53+/+ and HCT116 
p53-/- cells, glucose concentrations above 9mM were required to maintain cell 
survival under hypoxia with a pronounced drop in survival observed at 9mM (figures 
4.1 and 4.2) whereas survival of BE cells appeared unaffected by a reduction in 
glucose concentrations to 5mM. (figure 4.4). Although there is some variability 
between the six cell lines in response to low glucose conditions, consistently the 
cancer cells appeared much more dependent on glucose for cell survival under 





























Figure 4.1 Influence of glucose concentration on the survival of HCT116 p53+/+ cells. Panel A 
represents the survival of cells under different glucose concentrations under aerobic and hypoxic 
conditions and panel B presents representative images of cells under aerobic and hypoxic conditions 

































Figure 4.2 Influence of glucose concentration on the survival of HCT116 p53-/- cells. Panel A 
represents the survival of cells under different fructose concentrations under aerobic and hypoxic 
conditions and panel B presents representative images of cells under aerobic and hypoxic conditions 
(the values in parenthesis represent the concentration of fructose in the culture medium). 
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Figure 4.3 Influence of glucose concentration on the survival of HT29 cells. Panel A represents 
the survival of cells under different glucose concentrations under aerobic and hypoxic conditions and 
panel B presents representative images of cells under aerobic and hypoxic conditions (the values in 
































Figure 4.4 Influence of glucose concentration on the survival of BE cells. Panel A represents the 
survival of cells under different glucose concentrations under aerobic and hypoxic conditions and 
panel B presents representative images of cells under aerobic and hypoxic conditions (the values in 

































Figure 4.4 Influence of glucose concentration on the survival of DLD1 cells.  Panel A represents 
the survival of cells under different glucose concentrations under aerobic and hypoxic conditions and 
panel B presents representative images of cells under aerobic and hypoxic conditions (the values in 


































Figure 4.5 Influence of glucose concentration on the survival of PSN-1 cells. Panel A represents 
the survival of cells under different glucose concentrations under aerobic and hypoxic conditions and 
panel B presents representative images of cells under aerobic and hypoxic conditions (the values in 














4.3.2 Validation of results using the SRB assay 
The results of studies conducted using the SRB endpoint assay instead of the MTT 
assay for HT29 cells are presented in figure 4.7. These results demonstrate a similar 
trend to the MTT assay in that cell survival is reduced significantly in glucose 
deprived media under hypoxic conditions.  Direct comparison with the MTT assay 
results presented in figure 4.3 above show that under hypoxic conditions in the 
presence of 0.625mM glucose, cell survival values were similar in the SRB assay 
(30.65%) compared to the MTT assay (25.38%). Similarly in aerobic conditions and 
0.625mM glucose cell survival in the SRB assay was 93.64% and in the MTT assay, 
it was 94.71%. Based upon these findings, the MTT assay is generating data that is 







Figure4. 6 Influence of glucose concentration on cell survival using the SRB assay. The data 
represents the survival of HT29 cells after 96 hours of glucose deprivation media (0.625mM glucose) 
under aerobic (open bars) and hypoxic conditions (solid bars) using the SRB assay. The controls 
used medium containing 20mM glucose under both aerobic and hypoxic conditions. The values 








4.3.3 Recovery of cell survival following glucose deprivation for 96 hours. 
The results presented above demonstrate that glucose is required for cells to survive 
under hypoxic conditions but cell survival did not go below 10% suggesting that 
some cells were able to tolerate no glucose in the culture media in 0.1% oxygen 
conditions. To address the question of whether these surviving cells might be able to 
fully recover and commence proliferation when provided with glucose, glucose-rich 
media (20mM glucose) was added to cells following 96 hours of glucose deprivation. 
Cell survival was measured 48 hours after the addition of glucose-rich medium, and 
the results (white colour) are presented in comparison with glucose deprivation 
results (black colour) in figure 4.8.  
In the case of HCT116 p53+/+ cells, the addition of glucose rich media following 96 
hours of glucose deprivation had no effect on cell survival for cells incubated in 5mM 
glucose or less in the deprivation phase of the experiment (figure 4.8A). Whilst 
concentrations of glucose of 6 to 9mM significantly reduced the survival of cells 
under hypoxia, the addition of glucose rich media after the glucose deprivation 
period resulted in a significant increase in cell survival. Similar results were obtained 
for the HCT116 p53-/- cells although recovery was apparent only for cells exposed to 
7mM or more during the deprivation phase of the experiment (figure 4.8B).  
These results show that cells exposed for 4 days to glucose levels below 5 or 6mM 
under hypoxic conditions (0.1% oxygen) did not fully recover when glucose levels 
returned to normal. Above 5 to 6mM glucose however, HCT116 cells were able to 














Figure 4.7 Recovery of cells following glucose deprivation under hypoxic conditions. Panels A 
and B represents the recovery of HCT116 p53+/+ and HCT116 p53-/- cells respectively following 96 
hours of glucose deprivation. The values on the X-axis represent the concentrations of glucose used 
during the deprivation phase of the experiment and in all cases, glucose rich medium (20mM) was 
added at the end of the deprivation period. Cell survival was measured 48 hours later using the MTT 
assay. Please note that the results for glucose derived conditions are a repeat of the data presented 
in figures 4.1 and 4.2 and they are included here for the purpose of providing a direct comparison with 










4.3.4 Influence of oxygen tension and glucose concentration on the survival of 
cells.  
The results presented above were conducted at 0.1% oxygen. To determine the 
effect of glucose deprivation on cells at different oxygen concentrations, similar 
studies were conducted over a range of oxygen tensions. The results of these 
studies are presented in figures 4.9 and 4.10 
In the case of both HCT116 p53+/+ and HCT116 p53-/- cells, the effect of glucose 
deprivation is similar at 21% and 5% oxygen with effects on survival generally 
observed at very low levels of glucose. Even when glucose is absent, cell survival is 
typically above 60% of controls. The effects of glucose deprivation increased as 
oxygen tension is reduced with significant effects observed at 1% oxygen and these 
effects increase further as oxygen tension is reduced to 0.1%. The results are 
comparable in both cell lines.    
The results demonstrate that (i) the combination of low glucose and low oxygen 
tension have significant effects on cell survival and (ii) the magnitude of the effect on 



























Figure 4.8 Influence of oxygen tension and glucose concentration on HCT116p53+/+ cell 
survival. Panel A represents the survival of cells under different glucose concentrations and different 
oxygen tensions. Panel B presents representative images of cells exposed to different glucose 
concentrations (in parenthesis) and oxygen tension. Errors bars are present standard deviation for 






























Figure 4.9 Influence of oxygen tension and glucose concentration on HCT116p53-/- cell 
survival. Panel A represents the survival of cells under different glucose concentrations and different 
oxygen tensions. Panel B presents representative images of cells exposed to different glucose 
concentrations (in parenthesis) and oxygen tension, errors bars are present standard deviation for 
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4.3.5 Influence of different sugars on cell growth in vitro under aerobic and 
hypoxic conditions.  
The previous studies have demonstrated that under hypoxic conditions, cells are 
dependent upon glucose for survival. These conditions provide an experimental 
opportunity to determine whether or not other carbon sources can be utilised to 
maintain cell survival under hypoxic conditions. For comparative purposes, similar 
studies were performed under aerobic conditions and these are presented in figures 
4.11 (HCT116 p53+/+ cells) and figure 4.13 (HCT116 p53-/- cells).  Under normoxia, 
addition of lactate failed to increase survival above that of glucose-deprived cells. 
Galactose marginally increased survival in HCT116 p53+/+ cells. Mannose increased 
survival levels of ~60% in glucose-deprived HCT116 p53+/+ and HCT116 p53-/- cells 
to survival levels in cells cultured in glucose-rich media. 
Under hypoxic conditions only mannose was able to support the growth of cells in 
the absence of glucose. In both HCT116 p53+/+ and HCT116 p53-/- cells, mannose 
(10 mM) was able to completely reverse the effects of glucose deprivation (figures 
4.12 and 4.14). These results suggest that mannose could be a fuel that can be used 
alongside or instead of glucose to support the growth and survival of cells under 


























Figure 4.10 Effect of replacing glucose with various sugars on the survival of HCT116+/+ cells 
under aerobic conditions. Panel A represents the survival of cells grown with culture media without 
glucose but with different sources of carbon (mannose, lactate, galactose, and the combination of 
galactose with lactate) at (10mM) under aerobic conditions. Panel B presents representative images 
of treated cells under aerobic conditions (the values in parenthesis represent the concentration of 
sugar in the culture medium). The controls are media supplemented with glucose at 10 mM and 
glucose free media. 
Galactose (10mM) Glucose (10mM) 
Lactate (10mM) Mannose (10mM) 
Galactose and lactate (10mM) 


























Figure 4.11 Effect of replacing glucose with various sugars on the survival of HCT116 +/+ cells 
under hypoxic conditions. Panel A represents the survival of cells grown with culture media without 
glucose but with different sources of carbon (mannose, lactate, galactose, and the combination of 
galactose with lactate) at (10mM) under hypoxic conditions. Panel B presents representative images 
of treated cells under hypoxic conditions (the values in parenthesis represent the concentration of 
sugar in the culture medium). The controls are media supplemented with glucose at 10 mM and 
glucose free media.  
(A) 
(B) 
Mannose (10mM) Lactate (10mM) 
Free glucose (0mM) Galactose and lactate 
(10mM) 
























Figure 4.12 Effect of replacing glucose with various sugars on the survival of HCT116-/- cells 
under aerobic conditions. Panel A represents the survival of cells grown with culture media without 
glucose but with different sources of carbon (mannose, lactate, galactose, and the combination of 
galactose with lactate) at (10mM) under aerobic conditions. Panel B presents representative images 
of treated cells under aerobic conditions (the values in parenthesis represent the concentration of 
sugar in the culture medium). The controls are media supplemented with glucose at 10mM and 
glucose free media.  
Galactose (10mM) Glucose (10mM) 
Lactate (10mM) Mannose (10mM) 
Galactose and lactate 
(10mM) 


























Figure 4.13 Effect of replacing glucose with various sugars on the survival of HCT116-/- cells 
under hypoxic conditions. Panel A represents the survival of cells grown with culture media without 
glucose but with different sources of carbon (mannose, lactate, galactose, and the combination of 
galactose with lactate) at (10mM) under hypoxic conditions. Panel B presents representative images 
of treated cells under hypoxic conditions (the values in parenthesis represent the concentration of 
sugar in the culture medium). The controls are media supplemented with glucose at 10mM and 
glucose free media.  
Galactose (10mM) Glucose (10mM) 
Lactate (10mM) Mannose (10mM) 
Galactose and lactate (10mM) 










4.3.6 Comparison between the ability of glucose and mannose to support the 
growth of cells under hypoxic conditions.  
As described above, mannose can support the growth of cells under hypoxic 
conditions when glucose is absent. This series of experiments compares the relative 
efficiency of glucose or mannose to support growth under hypoxic conditions and the 
results are presented in figures 4.15 to 4.17.  
In the case of HCT116 p53+/+ and HCT116 p53-/- (figure 4.15), mannose was clearly 
superior to glucose in supporting the growth of cells under hypoxic conditions when 
compared at equimolar concentrations. Comparatively greater cell survival was 
observed in the presence of mannose at just almost all concentrations of mannose 
or glucose used, down to 1.25mM mannose in HCT116 p53+/+ cells (figure 4.15A) 
but differences were only seen down to 5mM mannose in the HCT116 p53-/- cells 
(figure 4.15B) suggesting a p53 related effect.  
In contrast to the HCT116 cell lines, the abilities of mannose or glucose to promote 
cell survival under hypoxia was similar in HT29, BE and PSN1 (figures 4.16A, 4.16B 
and 4.17B respectively). There was some evidence that mannose was superior to 
glucose in the case of DLD1 cells (figure 4.17A) but the magnitude of the effect was 
reduced compared to the HCT116 cell lines.  
These results demonstrate that mannose may be a more effective fuel than glucose 
under hypoxic conditions but this effect is cell line dependent and not a universal 

























Figure 4.14 Influence of glucose or mannose on the survival of cells under hypoxia (0.1% 
oxygen). Panel A represents the survival of HCT116 p53+/+ cells following 96 hours with glucose and 
mannose supplemented media (variable concentrations) and Panel B representing survival of 











Figure 4.15 Influence of glucose or mannose on the survival of cells under hypoxia (0.1% 
oxygen). Panel A represents the survival of HT29 cells following 96 hours with glucose and mannose 
supplemented media (variable concentrations) and Panel B representing survival of BE cells following 










Figure 4.16 Influence of glucose or mannose on the survival of cells under hypoxia (0.1% 
oxygen). Panel A represents the survival of DLD-1 cells following 96 hours with glucose and 
mannose supplemented media (variable concentrations) and Panel B representing survival of PSN1 










4.3.7 Influence of mannose to support the growth of DLD1 and PSN1 cells 
under hypoxic conditions.  
In a set of experiments that are similar in design to those described in figures 4.5 
and 4.6, the influence of mannose on the survival of DLD1 and PSN1 cells is 
presented in figure 4.18. The results presented in figure 4.18 are consistent with 
other cell lines in that mannose is being used as a fuel to support the growth and 


































Figure 4.17 Influence of mannose concentration on the survival of DLD1 cells. Panels A and B 
represents the survival of DLD1 and PSN-1 cells respectively over a range of mannose 











4.3.8 Influence of fructose and sucrose on the survival of HCT116 p53+/+ and 
HCT116 p53-/- cells under aerobic and hypoxic conditions.  
An additional series of experiments were conducted to broaden the spectrum of 
sugars evaluated to include sucrose and fructose as these sugars are commonly 
available in the diet. The objective of these experiments to determine whether or not 
they can serve as fuels to support the growth of cells under hypoxic conditions. The 
design of these experiments involved supplementation of glucose deprived medium 
with either sucrose or fructose (over a range of concentrations) followed by 
measurement of cell survival using the MTT assay 96 hours later. The results are 
presented in figure 4.19 to 4.22. The results show that in contrast to mannose, 
neither fructose nor sucrose are able to fully substitute for the absence of glucose in 
sustaining cancer cell survival.  
For both HCT116 p53+/+ and HCT116 p53-/- cells; fructose at high concentrations 
(15mM and 19mM) was shown to increase cell survival under aerobic conditions. 
Under hypoxic conditions, lower doses of fructose (10mM) had some beneficial 
effect but even at the highest concentration tested (19mM), survival was only ~40-
60% of that in glucose-rich media. Levels were restored to ~40% survival in HCT116 
HCT116 p53-/- cells suggesting possible p53-dependent differences in the ability of 
fructose to support survival under hypoxic conditions Addition of sucrose across the 
concentration range tested (0.625-19mM) failed to improve survival of glucose-
deprived cells (Fig. 4.21, 4.22) either under normoxic or hypoxic conditions. This 
suggests that sucrose is unable to substitute for glucose as an alternative fuel in 























Figure 4.18 Influence of fructose concentration on the survival of HCT116 p53+/+ cells. Panel A 
represents the survival of cells under different fructose concentrations under aerobic and hypoxic 
conditions and panel B presents representative images of cells under aerobic and hypoxic conditions 
(the values in parenthesis represent the concentration of fructose in the culture medium). Cell survival 
is expressed as a % relative to levels in the presence of 20mM glucose. 
(A) 
(B) (20mM) (20mM) 
(0.625mM) 

























Figure 4.19 Influence of fructose concentration on the survival of HCT116 p53-/- cells. Panel A 
represents the survival of cells under different fructose concentrations under aerobic and hypoxic 
conditions and panel B presents representative images of cells under aerobic and hypoxic conditions 




























Figure 4.20 Influence of sucrose concentration on the survival of HCT116 p53+/+cells. Panel A 
represents the survival of cells under different sucrose concentrations under aerobic and hypoxic 
conditions and panel B presents representative images of cells under aerobic and hypoxic conditions 
































Figure 4.21 Influence of sucrose concentration on the survival of HCT116 p53-/- cells. Panel A 
represents the survival of cells under different sucrose concentrations under aerobic and hypoxic 
conditions and panel B presents representative images of cells under aerobic and hypoxic conditions 
















4.3.9 Influence of L-glutamine and glucose deprivation on cell survival under 
aerobic and hypoxic conditions  
To examine dependency of cells on glutamine under normoxia and hypoxia and 
effects of both glucose and glutamine deprivation on cell viability under aerobic and 
hypoxic conditions, media was prepared with or without glucose (20mM) and/or 
glutamine (2mM). Cells were cultured in these media for 96 hours following which, 
cell survival was determined using the MTT assay. The results are presented in 
figure 4.23.  
Under aerobic conditions (open bars, figure 4.23), cells are able to survive in either 
the absence of glucose or in the absence of L-glutamine.                                                                                                                                                                                                                                                                                                                                                                                                                                                
In the absence of both glucose and L-glutamine however, cell survival was 
significantly reduced to ~10-20% of that of cells in media containing both glucose 
and glutamine. Overall, these results suggest that when glucose levels are low, 
aerobic cells can switch to L-glutamine metabolism. Furthermore, it suggests that 
strategies designed to target both glucose and L-glutamine metabolism may produce 
synergistic effects in vitro under aerobic conditions.  Under hypoxic conditions (solid 
bars, figure 4.23), however, the presence of glutamine failed to improve survival of 
cells cultured in the absence of glucose. This suggests that cells are unable to use L-
glutamine as an alternative fuel to support cell survival under hypoxia when glucose 








Figure 4.22 Influence of glucose and L-glutamine concentration on cell survival. Panel A 
represent the survival of HCT116 p53+/+ cells after 96 hours with 20 mM glucose (Glu +), without (Glu 
-) glucose, with 2mM L-glutamine (+ Glut) or without glutamine (- Glut). Panel B represent the same 










4.3.10 Influence of glucose and glutamine on cell sensitivity to the glutaminase 
inhibitor 968.  
The results presented in figure 4.24 demonstrate that the glutaminase inhibitor 
compound 968 is significantly more cytotoxic in the absence of glucose compared to 
glucose rich conditions. This was observed in both the HCT116 p53+/+ and HCT116 
p53-/- cells. The results suggest that in the presence of glucose, these cells can 
better tolerate inhibition of glutamine metabolism which is consistent with the results 
of Fig. 4.23 and effects of glutamine deprivation. It was also noted that the HCT116 
p53-/- cells were more sensitive to glutaminase inhibitor indicating p53-dependent 
effects. 
Figure 4.23 Response of HCT116 p53+/+ (left hand panel) and HCT116 p53-/- (right hand panel) 
cells to glutaminase inhibitor 968under aerobic conditions in the presence and absence of glucose. 
The results represent the mean ± standard deviation for three independent experiments. Drug 
exposures were continuous 96 hour exposures and cell survival was determined using the MTT 
assay.  
Glucose 













Cytotoxicity response of HCT116 p53+/+ and HCT116 p53-/- cell lines to 968 in  high 
glucose medium following 96 hours exposure under aerobic and hypoxic conditions 
is represented in figure 4.25 and figure 4.26. In aerobic conditions results showed 
that cells are not very sensitive to 968 (with IC50 >30µM). In hypoxic conditions 
HCT116 p53+/+ and HCT116 p53-/- cell lines were very sensitive to 968 with IC50 
values of 4.97 ± 1.65 µM and 8.6 ± 1.16 µM respectively (Fig. 4.26). In addition, the 
cytotoxicity response of HCT116 p53+/+ and HCT116 p53-/- cell lines to 968 in 
glucose free medium following 96 hours exposure under aerobic conditions is shown 
in figure 4.25C and 4.25D. Cells were very sensitive to 968 with IC50 values of 1.19 ± 

















Figure 4.24 Response of HCT116 p53+/+ and HCT116 p53-/- to 968 (96-hours exposure) in high 
glucose DMEM (panels A and B) and free glucose DMEM (panel C and D) media. These 
experiments were conducted under both aerobic and hypoxic condition and each value represents the 

































Figure 4.25 Response to 968 in high glucose DMEM (panels A HCT116 p53+/+ and panel B 
HCT116 p53-/- following 96-hours exposure under hypoxic condition. These experiments were 
conducted under both aerobic and hypoxic conditions and each value represents the mean ± 










4.3.11 The influence of glucose deprivation on cell viability and the cell cycle 
of HCT116p53+/+ and HCT116p53-/- cells cultured under hypoxic conditions.  
Cell viability and cell cycle   
High glucose and glucose free medium was tested for effects of glucose deprivation 
for 96h on the cell cycle of HCT116 p53+/+ and HCT116 p53-/- cells under hypoxic 
conditions alongside assessment of effects on cell viability (figure 4.27A and figure 
4.28 B and C). For HCT116 p53-/- cells (Figure 4.27B and Figure 4.29B and C), 
culture in glucose free medium caused an increase in sub G1 levels to ~50% of the 
total cell population consistent with effects observed on cell survival by 
chemosensitivity testing. Concomitant with this, the % of G1 phase cells decreased 
from ~50% to ~20%. For HCT116 p53+/+ cells (Figure 4.27A), culture in glucose free 
medium caused an increase in sub G1 to~60% of the total cell population and a 
concomitant decrease in G1 phase and S-phase populations.  
The effects of glucose deprivation on mitochondrial membrane potential, cell viability 
and total cell numbers are presented in figures 4.27 and 4.28. Incubation in glucose-
free medium (96hour) was shown to decrease cell viability in HCT116 p53+/+ and 
HCT116 p53-/- cells by 53% and 36% respectively. In addition, the mitochondrial 
membrane potential was measured as an indicator of early apoptosis and the results 
demonstrate that glucose deprivation under hypoxic conditions induces extensive 
membrane depolarisation. These results are consistent with the decrease in cell 









4.3.12 Assessment of glucose-free complete media for trace levels of glucose  
Glucose levels in cell culture media were measured by the Reflotron glucose assay. 
Glucose levels in high glucose medium were 19.5mM. In purchased glucose free 
medium supplemented with FBS (10%), l-glutamine (2 mM) and sodium pyruvate (1 




































Figure 4.26 Cell Cycle analysis. Panel A HCT116 p53+/+ cells grown in 20mM glucose  or free 
glucose medium for 96 hours under hypoxic conditions ,  Panel B HCT116 p53-/- cells grown in 20mM 
glucose or free glucose medium for 96 hours under hypoxic conditions.  
Glucose  No glucose  
























Figure 4.27 Cell viability, and determination of loss of mitochondrial membrane potential of 
HCT116 p53+/+ cells following 96 hours culture in high glucose or free glucose medium under hypoxic 
conditions. Panel A Quantification of mitochondrial membrane depolarisation using JC-1 stain. Panel 

























Figure 4.28 Cell viability, and determination of loss of mitochondrial membrane potential of 
HCT116 p53-/- cells following 96 hours culture in high glucose or free glucose medium under 
hypoxic conditions. Panel A Quantification of mitochondrial membrane depolarisation using JC-1 












4.3.13 Assessment of MPI and PMM2 expression following growth of cells in 
mannose or glucose-containing medium under aerobic and hypoxic 
conditions.  
Western blot analysis was performed to measure the expression of two key enzymes 
(MPI and PMM) involved in mannose metabolism which regulate whether or not 
mannose enters glycolysis or glycosylation pathways. The results are presented in 
figures 4.30 and 4.31. For MPI a band of 47kDa was expected. A band was 
observed around this size, however, lots of other non-specific bands were observed 
and without validation it is unclear whether the band at the correct size is actually 
MPI. Similarly, for   the PMM2 (Figure 5.30 B), detection of a specific band at the 
correct size proven difficult with lots of non-specific bands observed.  Attempts were 
made to reduce background by testing blocking the membrane with two different 
blocking buffers, 5% TBST-milk buffer (Figure 4.31 B) or LI-COR TBST buffer 
(Figure31A and Figure 30). Further work has been done in terms of detection of MPI 
and PMM2 protein expression by using ECL technique. Using ECL detection, much 
clearer bands were obtained on the Western blot as illustrated in figure 4.32. The 
results must be regarded as preliminary (n=1) but they do demonstrate that levels of 
MPI and PMM2 change under different experimental conditions (eg. normoxia versus 
hypoxia and glucose vs mannose). Further studies are required to determine 
whether the ratio of MPI to PMM2 reproducibly changes under the indicated  
experimental conditions, however, the results demonstrate that ECL detection 























 Figure 4.29 Western blot analysis of MPI in HCT116 p53-/- and HCT116 p53+/+ cells grown in 
mannose media and glucose media (20Mm) under aerobic and hypoxic conditions for 96hours 
using LI-COR system.   



























Figure 4.30 Western blot analysis of MPI in HCT116 p53-/- and HCT116 p53+/+ cells was grown 
up with mannose media (20Mm) under hypoxic and aerobic condition for 96hours using LI-COR 












Figure 4.32  Western blot analysis of MPI (Panel A), PMM2 (Panel B) and β-actin (Panel C) in 
HCT116 p53-/- and HCT116 p53+/+ cells grown in mannose or glucose media (20mM) under a 












This chapter assesses the influence of glucose deprivation on cancer cell lines under 
hypoxic and normoxic conditions and the ability of other carbon sources to 
substitute. There are a number of important and novel findings from this work. One 
key observation was the different dependency of normoxic and hypoxic cancer cells 
to glucose. For all six cancer cell lines tested, glucose deprivation had little effect on 
cell survival for cells grown under normoxic conditions. In contrast, hypoxic cancer 
cells showed a clear dependency on glucose for survival identifying a potential 
hypoxia-selective vulnerability that might be exploitable. A low proportion of the 
hypoxic cell population appeared to survive, however, recovery experiments 
indicated that these cells were unable to fully recover and proliferate. More in-depth 
analyses revealed that absence of glucose in the culture media under hypoxic 
conditions substantially increased the proportion of cells in subG1 and reduction in 
cell numbers and loss of cell viability was also evident by independent assays. This 
was supported by some studies that reported that glucose deprivation has shown 
apoptosis in colon  carcinoma, which showed the cells are a glucose dependent 
(Caro-Maldonado et al., 2010). The data presented here suggests that cell death of 
tumour cells induced by glucose deprivation is influenced by oxygen tension. This 
was also confirmed in a study by Palorini, in which it was demonstrated that 
transformed cells in medium with low glucose concentration (1 mM) proliferated 
more slowly than in medium with high glucose content (25 mM) (Palorini et al., 2013) 
but importantly, they also demonstrated that this effect was more pronounced in 








that glucose deprivation can induce apoptosis of cancer cells (Wise-Faberowski et 
al-,2001). 
The lack of much effect of glucose deprivation under normoxic conditions led us to 
hypothesise that cells under normoxia may utilise glutamine as a source of carbon to 
generate energy and support cell growth. To test this hypothesis, glutamine 
deprivation and glutamine inhibition experiments (using a glutaminase inhibitor) were 
performed which showed that glutamine was necessary to support survival under 
normoxic conditions in the absence of glucose.  In contrast, glutamine was unable to 
sustain hypoxic cells deprived of glucose. These results suggest that therapeutic 
strategies targeting glucose metabolism may be effective against hypoxic cells 
whereas for aerobic cancer cells dual targeting of both glucose and glutamine 
metabolism would be necessary. 
Experiments were also performed to investigate whether other sugars could be 
effectively used by hypoxic cells in place of glucose to support growth and survival. 
Sucrose, galactose, fructose, mannose and also lactate as the end product of 
aerobic glycolysis were tested. Lactate, the disaccharide sucrose and the 
monosaccharide fructose were all unable to support survival of hypoxic cells in the 
absence of glucose. Kamel and his group have reported that the monosaccharide 
galactose can be converted to glucose through the Leloir pathway, but that this 
process also requires energy (figure 4.32) (Kamel et al., 2014). Galactose was able 
to modestly increase survival of aerobic cancer cells but had no beneficial effect on 
hypoxic cell survival in the absence of glucose which relate to this requiring ATP to 









Figure 4.31 Summary of key metabolic pathways and how galactose and glucose interlink 
through the Leloir pathway (Kamel et al., 2014).   
In contrast to the other sugars tested, interestingly the results showed that mannose 
is able to fully support the survival of hypoxic cancer cells in the absence of glucose. 
Normally however, mannose is understood to be metabolised by cells primarily to 
support glycosylation of proteins rather than as a fuel source. Protein glycosylation is 
an important post-translational modification of proteins which is the covalent addition 
of mannose and other sugar moieties to proteins. Importantly, alterations in 
glycosylation are commonly observed in many cancers and increased glycosylation 
of cell surface proteins has been linked with increased cancer cell motility and 
invasive potential.  However, mannose can be converted to fructose 6 phosphate by 








et al., 1998). Figure 4.33 summarises these different pathways of mannose 
metabolism, mannose first being converted to mannose 6 phosphate (M6P) by 
hexokinase. M6P may then either be metabolised to mannose 1 phosphate 
(glycosylation pathway, catalysed by PMM2) or into glycolysis by conversion to F6P 
through the action of MPI. Preliminary investigations were performed to assess 
expression levels of these two key enzymes regulating mannose metabolism, PMM2 
and MPI, however, reliable detection by immunoblotting proved difficult.  
Nevertheless, the findings are very important and it is possible that in the context of 
the tumour microenvironment, in hypoxic cells mannose is diverted towards 
glycolysis. Based on the results presented here this may be very important for 
hypoxic cancer cell survival in glucose deprived conditions and is significant in the 
context of identifying new therapeutic approaches to target hypoxic cancer cells and 





    
 
Figure 4.32 Schematic summarising mannose metabolism and regulation of mannose 









Chapter 5  
Inhibition of glycolytic enzymes by silver complexes.  
5.1 Introduction 
The results presented in chapters 3 and 4 demonstrate that whilst cancer cells 
require glucose to survive under hypoxic conditions, current glycolytic inhibitors (eg. 
Sodium oxamate and Gossypol) do not significantly kill cancer cells under hypoxia. 
As these inhibitors can have non-specific effects on cells and work via similar 
mechanisms of action, other inhibitors of the glycolytic pathway may be more 
effective. The purpose of this chapter is to explore the effects of novel organometallic 
complex on glycolytic enzymes based upon previous studies in this laboratory 
demonstrating that they inhibit glycolysis. 
In a recent study by Allison et al (2017), a silver N-heterocyclic carbene (NHC) 
complex called Ag8 was shown to inhibit glycolysis in cell lines. The inhibition of 
glycolysis was determined by measurement of glycolytic rate using a XF96 metabolic 
analyser (seahorse Biosciences) in collaboration with colleagues at the University of 
Manchester and these studies demonstrated that Ag8 selectively reduced glycolysis 
and glycolytic reserve in a dose and time dependent manner in A2780 and OVCAR3 
cancer cells compared to non-cancer ARPE-19 cells. Whilst the ability of Ag8 to 
inhibit glycolysis is clear, it is not known where in the glycolytic pathway that the 
pharmacological inhibition occurs. Metal NHC complexes are of interest as potential 
inhibitors of glycolytic enzymes including lactate dehydrogenase (Rubbiani et al., 
2010). The major aim of this chapter was to determine whether or not Ag8 and other 








(hexokinase) in cell-free and cell-based assays. 
5.2 Materials and Methods 
5.2.1 Compounds 
A series of silver complexes were obtained from Dr Charlotte Willans (University of 
Leeds), details of which are presented in figure 5.1. The chemical synthesis of these 
compounds has been described elsewhere together with initial preclinical evaluation 
against a panel of cell lines in vitro (Allison et al., 2017).    
5.2.2 Inhibition of purified Rabbit muscle LDH.  
Purified L-lactate dehydrogenase from rabbit muscle was obtained from Sigma 
Aldrich (Poole, Dorset UK; L5132). All compounds were dissolved in DMSO at 
100mM, aliquoted and stored at -20C until required. LDH-A activity was determined 
by measuring the oxidation of NADH at 340nm as described in detail elsewhere 
(Song and Mechref).Briefly, each reaction consisted of NADH (100 µM), Sodium 
Pyruvate (600 µM), purified LDH (0.35 µg), solvent control (0.1% DMSO) or test 
compound (100 µM) in a total volume of 1ml Tris-HCl buffer (200mM, pH7.3). The 
reaction was started by the addition of NADH and the rate of change of absorbance 
(∆A/min) was determined at 340nm using a Cary 60 UV-Vis spectrophotometer over 
a 1 min period. Specific enzyme activity was determined using a molar extinction 
coefficient for NADH of 6.22 mM-1cm-1. Each reaction was performed in triplicate and 
percentage inhibition was calculated as 1 – (specific activity of treated LDH / specific 



























5.2.3 Analysis of LDH-A and LDH-B activity in a panel of cell lines.  
Analysis of LDH activity was determined in a panel of cell lines consisting of: 
HCT116 p53+/+, HCT116 p53-/-, HT-29, DLD1, PSN10.05, BE and ARPE-19. Cells at 
approximately 80% confluence were harvested by trypsinisation, washed twice in 
PBS before being re-suspended in Tris-HCl (0.2M, pH7.3). Cells were sonicated 
(Sonics and Material Vibro-cell VCX130 set at 50% amplitude for 3 x 30s bursts on 
ice) and cell lysates were used immediately for enzyme assays 
For LDH-A assays, each reaction contained 0.132 mM NADH, 0.6 mM Sodium 
Pyruvate and cell lysate (10μl) in a final reaction volume of 1 ml Tris-HCl (0.2M, 
pH7.3). The oxidation of NADH was determined over a 1 min reaction period at 
340nm using a Cary 60 UV-Vis spectrophotometer (Agilent Technologies).  
For LDH-B assays, each reaction contained 60mM sodium lactate, 0.132 mM 
sodium lactate and cell lysate (50 μl) in a final volume of 1 ml Tris-HCl (0.2M, pH7.3). 
The reduction of NAD was determined over a 1 min reaction period at 340nm using a 
Cary 60 UV-Vis spectrophotometer as above.  
In both cases, background rates of reaction were determined by omitting sodium 
pyruvate (for LDH-A) or sodium lactate (for LDH-B) from the reaction. Background 
rates were subtracted from full reaction rates to obtain true ΔA/min values. Protein 
concentration was determined using the Pierce BCA assay (described below) and 
specific activity (μmol/min/mg) was determined using the equation:  
Specific activity = ΔA/min / (ε x P) 








coefficient for NADH (6.220 mM-1cm-1) and P = total amount of protein in the cuvette.   
5.2.4 Determination of protein concentration using the Pierce BCA assay 
Protein concentrations in cell lysates were determined using the Pierce BCA assay 
(Thermo Fisher Scientific) according to manufacturer’s instructions. Briefly, cell 
lysates or BSA standards (2 mg/ml to 0.2 mg/ml) were added to a 96-well flat- 
bottomed plate (10μl per well, 4 wells per sample/standard). To this, 200μl of BCA 
reagent (1:50 mix of reagent B to reagent A) was added and following mixing, the 
plate was incubated at 37C for 30 min prior to reading the absorbance at 540nm in a 
Magnellan Tecan F50 spectrophotometer. A calibration curve was generated and the 
concentration of protein in unknown samples determined by reference to the 
calibration curve. If the absorbance of the samples exceeded the absorbance in the 
highest BSA standard used, the sample was diluted so that absorbance values 
within the calibration curve were obtained.  
5.2.5 Western blot analysis of LDH-A and LDH-B protein expression in a panel 
of cell lines.  
Cells at approximately 80% confluence were harvested by trypsinisation, washed 
twice in PBS before the addition of RIPA buffer (965 μl RIPA buffer plus 10μl 
phosphatase inhibitor and 25μl protease inhibitor). Cells were lysed on ice for 10 min 
following which they were sonicated for 3 x 30s at 50% amplitude as described 
above. The cell lysates were then stored at -20C until required.  
Samples 30μg were loaded onto SDS-PAGE gels (4% stacking and 15% separating 








the bromophenol blue dye had reached the bottom of the gel). The apparatus used 
was the mini-PROTEAN II electrophoresis system (Biorad).  
Following separation, proteins were transferred to nitrocellulose using the mini-
transblot apparatus (Biorad). Briefly, the separating gel was soaked in transfer buffer 
(200ml 10X transfer buffer [30g Tris base and 144g glycine in 1L dH2O], 400ml 
methanol, 20ml 10% ultrapure SDS and dH2O to a final volume of 2L) together with 
nitrocellulose paper, blotting paper and absorbent pads for 10min. The transfer 
‘sandwich’ was constructed according to manufacturer’s instructions and run at 
35mA for 2 hours.   
Following transfer, the nitrocellulose paper was washed in TBS-T (TBS plus 0.1% 
Tween 20). The membrane was then blocked overnight with TBS-T plus 5% Marvel. 
Following blocking, LDH antibody (rabbit monoclonal antibody, ab134187) was 
added at 1:1000 dilution to TBS-T and 5% Marvel and the nitrocellulose membrane 
incubated overnight in the fridge under constant agitation. The blot was washed 3 x 
in TBS-T for 5 min each wash before the secondary antibody was added (anti-rabbit-
HRP conjugated antibody from Dako. Following a one-hour incubation at room 
temperature, the blot was washed 3 x in TBS-T before chemiluminescent detection 
was performed using ECL (Amersham). Separate blots were also probed for β-actin 
using a primary rabbit monoclonal antibody from Chemicon International (MAB1510). 
The procedures were identical to above with the exception that the primary antibody 









5.2.6 Inhibition of LDH-A and LDH-B in cell lysates.  
Ag8 was dissolved in DMSO at 10mM and diluted to generate a range of drug 
concentrations ranging from 0.085mM to 10mM. Reaction conditions were as 
described above (5.2.3) and to each reaction 1μl of Ag8 was added prior to the 
addition of NAD(H). The final DMSO concentration therefore was 0.1% v/v in all 
cases including the control. Specific enzyme activities were calculated as describe 
above and each reaction was repeated in triplicate (per experiment) and a total of 
three independent experiments were performed. 
5.2.7 Release of lactate from cell cultures.   
The release of lactate from HCT116 p53+/+ and HCT116 p53-/- cells was determined 
enzymatically based upon the conversion of lactate to pyruvate by lactate 
dehydrogenase. Cells were placed in either T25 or T75 flasks and grown to various 
levels of confluence to determine the best conditions to measure lactate release. In 
all cases, culture media was removed at various times following the addition of fresh 
culture medium and this was centrifuged at 13,000 rpm for 30s to remove any cells 
that may have been in suspension. Each reaction consisted of 0.5 ml of culture 
media and 0.5ml of a hydrazine buffer (60.5g Tris base, 2.92g EDTA and 6.5g 
hydrazine dissolved in 500ml of dH2O and pH adjusted to 9.8) containing L-Lactate 
dehydrogenase and NAD. The reaction was monitored at 340nm over a one min 
reaction time and the rate of change of absorbance determined using a Cary 60 UV-
Vis spectrophotometer. A calibration curve was generated using culture media 








To determine whether Ag8 inhibited the release of lactate from cells, cells were 
treated with Ag8 at 5μM and 10μM and lactate release was monitored at various 
time points up to a maximum of 24hours. The concentration of lactate in the media 
was determined using the calibration curve and each experiment was performed in 
triplicate.  
5.2.8 Analysis of the effect of Ag8 on NAD(H) and NAD/NADH ratios.  
Analysis of NAD(H) in cells was conducted using the assay described by Allison et al 
(2014). Briefly, HCT116 p53+/+ and HCT116 p53-/- cells were seeded into T75 flasks 
at 1.5 x 106 cells per flask and incubated at 37ºC for 4 days prior to treatment with 
Ag8. Cells were treated with Ag8 (various concentrations as defined in the results 
section) and cells were harvested at various time points by first washing the 
monolayer twice with PBS followed by the addition of 1 ml of extraction buffer (20mM 
Sodium Bicarbonate, 100mM Sodium Carbonate, 10mM Nicotinamide and 0.05% 
Triton-X-100). The extraction buffer was swirled around the flask until all cells had 
lysed and a ‘jelly like’ lysate had formed. The lysate was transferred to Universal 
tubes and sonicated on ice as described previously (see section 5.2.3).  
The lysate was separated into two vials, one of which was heated at 60ºC for 30min 
to degrade NAD. The other vial was kept on ice. Each 1ml reaction consisted of 
0.830ml Cycling buffer (100mM Tris HCL (pH.8.0), 5mM EDTA and 0.5mM MTT), 
10µl Alcohol Dehydrogenase (20mg/ml), 10µl PES (200mM) and 50µl of sample or 
standard (NAD or NADH). The reaction started by adding 100µl of 6M ethanol to the 
cuvette and the absorbance was read at 570nm for 30 seconds using a Cary UV-Vis 








standard.   
A calibration curve using either NAD or NADH (100μM to 0.78μM) was generated 
using the procedure above. Using this calibration curve, the unheated sample 
provides the total NAD(H) in the sample and the heated sample directly measures 
the concentration of NADH in the sample. The difference between the two is the 
concentration of NAD. The values for NAD(H), NAD and NADH were normalized 
relative to protein concentration which was determined using the Pierce BCA assay 
as described above (see section 5.2.4).  
 
5.2.9 Inhibition of hexokinase by silver complexes 
The ability of silver complexes to inhibit yeast (Saccharomyces cerevisiae) 
hexokinase was determined using a coupled reaction as described below: 
 
Glucose + ATP                                                          Glucose 6 Phosphate + ADP 
 
Glucose 6 phosphate + NADP                                   6 phospho gluconate + NADPH 
Each reaction consisted of NADP (14mM), ATP (19mM), G6PDH (Glucose 6 
phosphate dehydrogenase, 125 units), d-glucose (555mM) and purified hexokinase 
(4 units) in a total volume of 1ml triethanolamine buffer (50mM, pH 7.6). The reaction 










monitored at 340nm over a period of 1 min. All silver compounds were dissolved in 
DMSO at 100mM and the final concentration of each compound in the reaction was 
100μM.  
5.3 Results 
5.3.1 Inhibition of purified rabbit lactate dehydrogenase.  
The ability of silver complexes and cisplatin to inhibit purified rabbit lactate 
dehydrogenase is presented in figure 5.2. Cisplatin was used in order to compare 
the activity of novel silver complexes with an established anti-cancer drug that is 
approved for use in humans but which is not reported to inhibit LDH. At a 
concentration of 100 μM, HB13, HA236, HA201 and cisplatin had minimal effects on 
the activity of rabbit LDH. In contrast, HA266, NL26 and Ag8 completely inhibited 
rabbit LDH in this cell free assay. The other compounds also inhibited rabbit LDH but 









Figure 5.2 Inhibition of purified rabbit muscle lactate dehydrogenase by a series of silver 
complexes and cisplatin (CIS20). The concentration of each compound in this initial test was 100 
μM and each value represents the mean ± standard deviation for three independent experiments.  
5.3.2 Specific activity of LDH-A and LDH-B in a panel of cell lines  
The specific activity of LDH-A and LDH-B in a panel of cell lines is presented in 
figure 5.3. In all cases, the activity of LDH-A was significantly higher than LDH-B. 
Whilst LDH-B activity was highest in the non-cancer ARPE-19 cell line, LDH-A 



















Figure 5.3 Specific activities of LDH-A and LDH-B in a panel of cell lines. Each value represents 
the mean ± standard deviation for three independent experiments.  
 
5.3.3 Protein expression of LDH-A and LDH-B in a panel of cell lines 
The results of western blot analysis of LDHA and LDH-B in a panel of cell lines is 
presented in figure 5.4. These results are preliminary and only one run of the 
experiments was possible due to time constraints. Nevertheless, the results 








HCT116 p53-/-, HT-29, DLD-1, BE and ARPE-19 cells. No LDH-B was visible in 
PSN10.05 cells. LDH-A levels varied across the panel of cells however there were 
more marked variations in LDH-B intensity with strong bands present in HCT116 and 
DLD1 cells and low levels in BE and PSN10.05 cells. Protein loading as indicated by 
























5.3.4 Inhibition of LDHA and LDH-B in cell lysates.  
The ability of Ag8 to inhibit human LDH derived from BE cell lysates is presented in 
figure 5.5. Whilst Ag8 does partially inhibit LDH-B at 10μM, Ag8 preferentially inhibits 
LDH-A with significant inhibition at 5μM compared to no inhibition of LDH-B at the 
same dose. Ag8 is therefore a selective inhibitor of LDH-A compared to LDH-B with 













                                                                       
Figure 5.5 Inhibition of LDH-A (A) and LDH-B (B) and percentage activity remaining (C) in cell 
lysates from BE cells treated with Ag8. Each value represents the mean ± standard deviation from 









5.3.5 Release of lactate from cells in culture.  
The calibration curve using media spiked with various concentrations of sodium 
lactate is presented in figure 5.6. The results demonstrate that the regression 
analysis does not go through zero and at higher concentrations of lactate, the data 
points for a distinct curve. Regression analysis is not suitable for this data and 
concentrations of lactate were read manually off the calibration curve 
 
Figure 5.6 Lactate calibration curves using a narrow and broad range of lactate concentrations 
(left and right hand panels respectively). The straight lines represent the result of linear regression 










Using these calibration curves, the number of cells required to detect lactate release 
in cell culture media was determined over a 24 hour period (figure 5.7). An initial 
seeding density of 1 x 105 cells per T25 flask did not result in significant levels of 
lactate in culture media 24 hours after starting the experiment. Lactate release was 
detectable using 1 x 106 cells per T25 flask and this improved further if cells were left 
until approximately 80% confluent (figure 5.7, left hand panel). In this case, the rate 
of lactate release was similar across all time points ranging from 0.54mM/h to 
0.39mM/h at the 2 hour and 8 hour time points respectively (figure 5.7, right hand 
panel). 
Figure 5.7 Release of lactate from HCT116 p53-/- cells.  In the left hand panel, the levels of lactate 
released from cells over a 24 hour period was determined at three different cell culture states. These 
were, 24 hours after seeding T25 flasks with 1 x 105 cells or 1 x 106 cells and 5 days after seeding 1 x 
106 cells to get cultures that are approximately 80% confluent. The right hand panel presents the rate 
of release of lactate at the various time points specified using cultures that are at 80% confluence. 








The effect of Ag8 on the release of lactate from HCT116 cells is presented in figure 
5.8. Extracellular lactate was undetectable in the cell culture media up to 6 hours in 
both cell lines (HCT116 p53+/+, HCT116 p53-/-).  Extracellular lactate was detected at 
8 and 24 hours (figure 5.8).  In HCT116 p53-/- cells, Ag8 induces a dose dependent 
reduction in extracellular lactate at 8 hour and 24 hour time points (*P<0.01). In 
contrast, in the HCT116 p53+/+ cells no effect of Ag8 was observed at 8 hours whilst 
at 24h a decrease in extracellular lactate was observed at 5 and 10uM Ag8 but this 









Figure 5.8 The effect of Ag8 on extracellular levels of lactate in HCT116 p53-/- and HCT116 
p53+/+ cells. Cells were at 80% confluence before treatment with Ag8 commenced and the time on 
the X-axis represents both the duration of drug exposure. The results presented are the mean of three 
independent experiments and the error bars represent standard deviation values. *P<0.01, unpaired 








5.3.6 Effect of Ag8 on NAD, NADH, NAD(H) and the NAD/NADH ratio. 
Calibration curves using both NAD and NADH are presented in figure 5.9. In both 
cases, there is a linear relationship between NAD(H) and ΔA/min with virtually 
identical regression analysis results.  
 
Figure 5.9 Calibration curves for NADH and NAD. Each value represents the mean ± standard 
deviation for three independent experiments. 
Validation of the heating step in the reaction is shown in figure 5.10 and this 
demonstrates that whilst NADH is stable at 60C for 30min, NAD is almost completely 
lost. There was some very low level activity present but compared to the non-heated 
















Figure 5.10 Validation of the NAD(H) assay. The concentration of NAD and NADH in these 
reactions was 100μM in both cases and both samples were either heated at 60C for 30min (H) or not 
heated (NH). Each value represents the mean ± standard deviation for three independent 
experiments.  
Prior to measuring the effect of Ag8 on NAD(H) levels, the morphological effects 
induced by Ag8 following a one hour exposure were determined to see if major short 
term effects were being observed (short term exposures to Ag8 had not been 
performed previously. The results are presented in figure 5.11 and these clearly 
demonstrate that Ag8 is inducing significant morphological damage to both HCT116 
p53+/+ and HCT116 p53-/- cells following a one-hour exposure to Ag8 (50μM). As the 
concentration of Ag8 decreases, morphological effects become less visible and at or 
below 20μM, there are no major effects visible under the microscope. A 








in cells. These concentration was selected based on effect of Ag8 at 5μM and 10μM, 
on lactate released up to 24 hours time exposure.     
 
Figure 5.11 Morphological effects of different doses Ag8 following short time exposure. Cells 



















Treatment of HCT116 p53-/- cells with Ag8 (20μM) had significant effects on redox 
levels within the cell as illustrated in figure 5.12. Whilst the levels of total NAD(H) did 
not significantly change during the 45min drug exposure period, there was a 
significant and rapid rise in NAD levels with a corresponding drop in NADH. Effects 
were observed within 5 min of drug treatment and it peaked at 10 min before 
dropping back to a steady state between 15 and 45 min. The levels in this steady 
state phase were much higher (in the case of NAD) or lower (in the case of NADH) 
than control (t = 0) levels. The effect on the NAD/NADH ratio was significant with a 


































Figure 5.11 The effect of Ag8 on the levels of NAD and NADH in HCT116 p53-/- cells. The upper 
graph presents the levels of NAD, NADH and NAD(H) and each value represents the mean ± 








5.3.7 Inhibition of hexokinase by silver complexes 
The ability of a series of silver complexes to inhibit purified yeast hexokinase is 
presented in figure 5.13. Whilst cisplatin does not inhibit hexokinase, several silver 
complexes did. These include 100µM of HB16, HA201, HA266 and Ag8 where 
hexokinase activity was almost completely inhibited. The other compounds in the 
series were partial inhibitors of hexokinase under the experimental conditions used 
here.  
Figure 5.12 Inhibition of yeast hexokinase by silver complexes. The left hand panel presents the 
specific enzyme activities and the right hand panel presents the % inhibition based upon the specific 
activity of test compounds relative to the control. The data in the left hand panel represents the mean 









5.4 Discussion  
Recent collaborative research with the University of Manchester has identified the 
silver N-heterocyclic carbene complex Ag8 as a potent and selective inhibitor of 
glycolysis in cancer cells (Allison et al., 2017). However, the cellular target or targets 
of Ag8 that result in this inhibition of glycolysis have yet to be identified. This chapter 
investigates the ability of Ag8 to inhibit key glycolytic enzymes LDH-A and 
hexokinase (HK), as well as LDH-B which promotes the reverse enzymatic reaction 
(conversion of lactate to pyruvate) to that of LDH-A. In addition, ten novel silver 
organometallic complexes were analysed alongside Ag8 for possible effects as well 
as cisplatin as a control.  
In a cell-free assay of LDH-A activity, Ag8 as well as many of the other silver 
complexes at the single tested concentration of 100µM strongly inhibited LDH-A, 
whereas cisplatin and four of the series of novel silver complexes had very little 
effect (<10% inhibition). This prompted our investigation of LDH-A and LDH-B 
expression and activity in a range of cancer cell lines and the ability of Ag8 to inhibit 
LDH-A and LDH-B in cell lysates. Preliminary expression data is presented and 
needs repeating, however, LDH-A activity was readily detectable in all cell lines 
tested (Fig. 5.3). In BE colorectal cancer cell lysates, Ag8 inhibited LDH-A at low 
micromolar concentrations with an IC50 of 1.8µM compared to >10µM for inhibition of 
LDH-B. This is significant as many of the existing LDH inhibitors lack good selectivity 
towards one isoform or the other and this work identifies Ag8 as a selective inhibitor 
of LDH-A. This also provides a mechanistic explanation for the reported inhibition of 









LDH-A inhibition has previously been reported to reduce extracellular lactate levels 
and alter intracellular NAD(H) redox balance (Allison et al., 2014). This is consistent 
with LDH-A enzyme catalysing the NADH-dependent reduction of pyruvate to 
lactate. The effects of Ag8 on lactate and NAD(H) levels were therefore also 
investigated. 5µM concentrations of Ag8 consistently reduced extracellular lactate 
levels in both HCT116 p53-/- and p53+/+ cancer cells with sampling times ranging 
from 2h up to 24h. Effects on NAD(H) were also investigated, in this case, in 
response to an acute up to 45min) treatment with 20µM Ag8. Whilst total cellular 
levels of NAD(H) did not change over this duration, NAD levels rapidly increased 
within 5 minutes. It is unclear whether this relates to LDH-A inhibition, however, or 
other effects on cellular metabolic flux and this warrants future experimental 
investigation. Indeed, Ag8 was also found to potently inhibit hexokinase in a cell-free 
assay, however, this has yet to be investigated using cell lysates. It is also 
noteworthy that across the panel of novel silver complexes screened here, whilst 
some of the complexes inhibited both LDH-A and HK in cell-free assays, selective 
inhibition of either LDH-A or HK was also observed for several complexes. For 
example, whilst Ag8 inhibited both LDH-A and HK, the related complex HA201 had 
little effect on LDH-A activity but strongly inhibited HK. Given the dependency of 
hypoxic cancer cells on glucose for their survival as presented in chapter 4, this is an 
interesting series of compounds for further studies as potential hypoxia targeting 












The metabolic reprogramming of cancers to favour aerobic glycolysis over oxidative 
phosphorylation and the emerging evidence that oncogenic events drive this process 
is of considerable interest as a target for therapeutic intervention (Yeung et al., 2008, 
DeBerardinis et al., 2008a). Whilst considerable attention has focused on the 
Warburg effect under aerobic conditions, there is another level of complexity that has 
received comparatively less attention and that is the metabolic phenotype under 
hypoxic conditions (Devic, 2016). The problem of hypoxia remains a significant 
challenge for drug discovery and strategies such as hypoxia activated prodrugs have 
not generated effective anti-cancer drugs so far (Phillips, 2016). New approaches to 
target hypoxic cells are required and the primary objective of this thesis was to 
determine whether or not targeting cancer cell metabolism under hypoxia results in 
preferential cell kill under these conditions.   
In the first of the major chapters in this thesis, the ability of a range of metabolic 
enzyme inhibitors to preferentially kill hypoxic cells was evaluated. The inhibitors 
used include 2-deoxyglucose (2-DG) which is phosphorylated by the enzyme 
hexokinase and accumulates in the cell leading to inhibition of hexokinase (Zhang et 
al., 2006). 2-DG also causes ATP deficiency and cell death, especially in cells with 
mitochondrial defects under hypoxic conditions (Maher et al., 2004). In this study, 
2DG caused a decrease in cell viability under both aerobic and hypoxic conditions 








exception of BE cells (table 3.4). The potency of 2-DG was low and this is consistent 
with other studies that reported that 2-DG might not be a potent inhibitor of tumour 
metabolism (Ledoux et al., 2003). In addition, there are reports in the literature 
showing that hypoxic cells are more resistant to 2-DG under hypoxic conditions 
(Maher et al., 2007). Other studies have reported that 2-DG should always used in 
combination with other drugs rather than as a single agent (Bénéteau et al., 2012) 
and further studies should be conducted to explore this further. The results of this 
study demonstrate that 2-DG is not a potent compound and is less effective against 
hypoxic compared to aerobic cells in vitro with the exception of BE cells where a 
HCR of 1.46 was obtained.  
Another inhibitor used was 3-bromopyruvate (3-BP) which is also a hexokinase 
inhibitor. All tumour cell lines responded to 3-BP under both aerobic and hypoxic 
conditions but without showing any hypoxic selectivity (table 3.4). In fact, cells under 
hypoxia were less sensitive to 3-BP than under aerobic conditions with HCR values 
of 0.34 to 0.62. Ko et al. were reported that 3-BP inhibits mitochondrial respiration 
and hexokinase at low concentrations in vitro (Ko et al., 2001). The doses used in 
this study are consistent with these values and inhibition of hexokinase should have 
occurred. No enzyme inhibition studies were conducted however because the HCR 
values were low in the initial screen.   
Similarly, sodium oxamate did not show any significant selectivity for hypoxic cells in 
vitro. Indeed, cells were more resistant under hypoxia than aerobic conditions with 
HCR values ranging from 0.87 to 0.69 (table 3.4). Sodium oxamate is an inhibitor of 








mechanisms of action (Moreno-Sánchez et al., 2017). Other studies have 
demonstrated that LDH-A specific inhibitors have hypoxia selectivity (Granchi et al., 
2011) and behave synergistically with other anticancer drugs (Maftouh et al., 2014). 
The lack of hypoxia selectivity observed in this study using sodium oxamate may 
reflect the fact that it is not a good inhibitor of LDH-A.  
To conclude this section of the thesis, this study has demonstrated that the use of 
established glycolytic inhibitors did not demonstrate hypoxia selectivity in vitro and in 
the majority of cases, resistance under hypoxia was observed. The hypoxia activated 
prodrug tirapazamine did produce good HCR values confirming that the experimental 
conditions used were suitable. These results raise questions as to whether or not 
glycolysis under hypoxic conditions is important for cell survival but the fact that 
other glycolytic inhibitors have shown hypoxia selectivity in vitro (Granchi et al., 
2011)  suggests that targeting glycolysis under hypoxia is a potential strategy for 
hypoxia selectivity.   
In addition to glycolytic inhibitors, this study also focused on the inhibiton of pyruvate 
kinase 1 (PDK1) using dichloroacetate (DCA). DCA is an inhibitor of PDK1 leading to 
activation of the pyruvate dehydrogenase complex and causes a shift back to 
oxidative phosphorylation and induction of apoptosis (Bonnet et al., 2007, Michelakis 
et al., 2008, Stacpoole et al., 2008). The results of this study demonstrate that DCA 
is more potent under hypoxia than aerobic conditions in some cell lines but not 
others (table 3.1) with HCR values ranging from 2.09 to 1.11 For HCT116 p53+/+, 
PANC 10.05, HT-29, HCT116 p53-/-, SW48 and BE cells. These effects are modest 








cancer ARPE-19 cells, DCA was less active under hypoxic conditions than aerobic 
conditions. The results were significant and suggest that DCA maybe less active 
against hypoxic normal cells in tissues such as the bone marrow (Bonnet et al., 
2007). Much more detailed research needs to be done to confrim this but the result 
is interesting. The mechanism underpinning these differential effects is not known. 
Western blot analysis does show that DCA is inhibiting PDK1 (reduced levels of p-
PDH) and this is consistent with other studies in the literature (Crewe et al., 2017). 
Further studies are however required to explore the reasons why HCR values are 
different between HCT116p53+/+ and ARPE-19 for example.  
The potency of DCA was low (mM range) but this is consistent with other studies in 
the literature (Bonnet et al., 2007). Also, the effectiveness of DCA is very different 
between different cancer cell lines and in some cases, DCA did not demonstrate a 
direct cytotoxic effect in vitro (Shahrzad et al., 2010, Zheng and Shen, 2013). The 
low potency of DCA may be related to the fact it is a weak inhibitor of PDK1 (McFate 
et al., 2008) and more effective inhibitors of PDK1 may have greater potency and 
increased HCR. In addition, synergy between PDK1 inhibitors and other 
chemotherapeutic agents have been documented in monolayer cultures (Sradhanjali 
et al., 2017) and further studies using three dimensional models (eg spheroids) that 
mimic more closely the microenvironment of tumours are required (Asghar et al., 
2015). 
With the exception therefore of DCA, the results of this study have demonstrated that 
established glycolytic inhibitors do not selectively kill hypoxic cells in vitro and in 








survival of cells in hypoxic conditions may not in fact depend on glucose metabolism 
as proposed in the rationale for this thesis. This raised the question of whether or not 
cells require glucose to survive under hypoxia and the studies in chapter three 
address this question. When glucose was removed from the media, cells survived 
under aerobic conditions but not under hypoxic conditions (figure 4.23). The effect of 
glucose deprivation was concentration dependent and at concentrations below 8mM, 
the suppression of growth could not be rescued when glucose was supplied after a 
96 hour deprivation period (figure 4.8). These results confirm that cancer cells 
require glucose to survive under hypoxic conditions suggesting that hypxic cells are 
glycolysis depending  to generate energy rquired in cell growth, but this raises the 
intriguing question as to why hypoxic cells are not extremely sensitive to glycolytic 
inhibitors? It is clear that other mechanisms are able to ‘get around’ the block in 
glycolysis or that inhibition of glycolysis is incomplete and even a low level of 
glycolytic flux is sufficient to keep the cells alive.  
The results showing that glucose deprivation reduces cell survival provided an 
opportunity to determine whether other sugars are important for the survival of 
cancer cells under hypoxia. By adding various sugars to glucose deprived media, it 
was possible to determine which sugars are able to promote cell survival when 
glucose levels are low. A somewhat suprising result was the lack of any increase in 
survival when lactate was added to glucose deprived media. Lactate is a potential 
fuel and the lack of any effect on hypoxic cells was uexpected. It has recently been 
shown however that glucose deprivation upregulates the lactate transporter MCT1 








Furthermore, this result is consistent with the model proposed by Sonveaux et al 
where lactate produced by hypoxic cells is used as a fuel to support the growth of 
oxygenated cells (Sonveaux et al., 2008). The most striking result obtained in these 
studies was with mannose which was able to completely reverse the effects of 
glucose deprivation. This suggests that mannose in addition to glucose are important 
sugars that promote the survival of cancer cells under hypoxic conditions. To the 
best of my knowledge, this is a novel finding and it opens up a new avenue of 
research.  
Mannose is a simple sugar but its biochemistry and physiological function is complex 
(Sharma et al., 2014). Its metabolism is illustrated in figure 6.1 and following 
transport into the cells via GLUT transporters, it is converted to mannose-6-
phosphate by hexokinase. It can then be either catabolised by conversion to 
fructose-6-phosphate by phosphomannose isomerase (MPI) or used to produce 
mannose-1-phosphate by phosphomannomutase (PMM1) which is then used in the 
synthesis of N-glycans (figure 6.1). The ratio of MPI to PMM1 largely determines 
which pathway mannose-6-phosphate goes down with higher ratios favouring entry 
into glycolysis. It is therefore possible that mannose could be an alternative source of 










Figure 6.1 Metabolism of mannose (Sharma et al, 2014).  
The levels of mannose in human plasma have been quantified and these are 
generally around 50 M(Sharma and Freeze, 2011) and this is well below the levels 
required to restore cell survival under conditions of glucose deprivation. Typically, 








hypoxic conditions. If mannose is important in promoting hypoxic cell survival, the 
key question that needs to be addressed is where is the mannose coming from if 
circulating levels of mannose are in the M range? Mannose is the major sugar 
(monosaccharide) present in N-glycans which are attached to proteins to form 
glycoproteins that play multiple roles in cells including cell-cell interations. More than 
50% of human proteins are believed to be glycosylated and abherent glycolsylation 
is associated with several disease types including cancer (Song and Mechref, 2015). 
Altered glycosylation of proteins also plays an important role in the metastatic 
process (Oliveira-Ferrer et al., 2017) and hypoxia is known to regulate glycosylation 
reactions via HIF1 mediated reactions (Shirato et al., 2010). Furthermore, 
glycoproteins can be ‘recycled’ by degradation in the cytoplasm and lysosome 
resulting in the release of free mannose (Aebi et al., 2010, Chantret and Moore, 
2008). Hypoxia is also known to induce autophagy (Fang et al., 2015) and 
autophagy has been shown to play a role in recycling glycoproteins (Huang et al., 
2015) The evidence in the literature demonstrates a clear link between N-glycan 
biology and catabolic metabolism and it is possible that recycling of glycoproteins 
could provide cells with the mannose required to enter glycolytic reactions and 
promote survival under hypoxic conditions. The link to metastasis is also interesting, 
especially as hypoxia is a known ‘driver’ of the metastatic process(Rankin and 
Giaccia, 2016) To conclude this part of the thesis, mannose has been shown to 
promote cell survival under hypoxic conditions and further studies are required to 
explore the possibility that release of mannose from N-glycans occurs under hypoxia 








Also within chapter 4, studies demonstrated that cells survived in the absence of 
glucose under aerobic conditions suggesting that alternative sources of energy were 
being used for catabolic purposes. Cell survival significantly decreased however 
when both glutamine and glucose were depleted from the media. These results are 
consistent with other studies in the literature (Wise et al., 2008) and suggest that 
targeting both glycolysis and glutaminolysis could produce synergistic effects.  
Subsequently, the cells were tested with 2DG (hexokinase inhibitor) and 968 
(glutaminase inhibitors) using high glucose medium and glucose-free medium (in the 
presence of glutamine). The response of cells treated with 2DG and 968 in glucose-
free medium showed that both inhibitors increase cell death. These results 
suggested that by targeting metabolic pathway of cancer cells in combination with 
HK inhibitors and glutaminase inhibitors might induce effective results for targeting 
cancer cells.  Also, the response of cancer cells to 968 was tested under hypoxic 
conditions in high glucose medium for 96 hours. 968 had a significant effect on both  
HCT116 p53+/+ and HCT116 p53-/- cells under hypoxic condition compare to aerobic 
conditions (figure. 4.25 and 4.26). Under hypoxic conditions, it has been shown that 
glutamine metabolism is required for the synthesis of lipids that are required to 
promote cell growth instead of entry into the TCA cycle (Sun and Denko, 2014).The 
potentiation of 968 activity under hypoxia is therefore consistent with the findings of 
Sun and Denko (Sun and Denko, 2014).  
The final results chapter of this thesis focused on the evaluation of a series of silver 
complexes as inhibitors of lactate dehydrogenase (and hexokinase). This study 








explored in greater depth due to the fact that previous studies had studied its 
pharmacological properties in detail (Allison et al, 2017). Ag8 is a silver N-
heterocyclic carbene (NHC) complex that has been shown to inhibit glycolysis is 
cancer cells (Allison et al 2017) but the inhibition of LDH is a novel finding for this 
class of compound. The kinetic nature of the inhibition of purified LDH is not known 
but Ag8 selectively inhibits LDH-A compared to LDH-B in cell lysates. The reduction 
in lactate release from cells is also consistent with the inhibition of LDH-A but it is 
also conceivable that inhibition of the MCT4 transporter (which exports lactate out of 
the cell) could also result in reduced extracellular lactate levels. Copper and zinc 
bipyridyls have been shown to inhibit LDH (Koiri et al., 2008) but this is the first 
report of a silver NHC complex selectively inhibiting LDH-A. 
Inhibition of LDH-A using siRNA led to a significant decrease in the NAD/NADH ratio 
in cancer cells (Allison et al 2014) but in this study, there was a rapid and significant 
increase in NAD levels in cells treated with Ag8. Significant effects were observed 
within 5 min of adding Ag8 and whilst the magnitude of these changes decreased to 
a steady state, the levels of NAD remained higher than control levels. These results 
are not consistent with the inhibition of LDH-A indicating that other mechanisms are 
operating. Ag8 is known to inhibit several key enzymes including NAD dependent 
enzymes such as PARP (Allison et al 2017). It is possible therefore that inhibition of 
NAD dependent enzymes could cause elevated levels of NAD but this hypothesis 
requires further investigation. This study also demonstrated that Ag8 induces very 
rapid morphological changes in cells with loss of viability occurring within one hour of 








the effects were less dramatic. The mechanism of cell death is not known however 
and further studies are required to explore this further. In conclusion, this chapter 
has demonstrated that Ag8 is a novel selective inhibitor of LDH-A that causes a 
significant reduction in the release of lactate from cells. Further studies are required 
to determine whether this leads to hypoxia selectivity in vitro but this is a promising 
hit compound for further studies.     
 
In conclusion, this thesis has demonstrated that the use of glycolytic inhibitors does 
not result in hypoxia selective cell kill in vitro. DCA however does show a degree of 
hypoxia selectivity but the magnitude of the enhancement is lower than the HAP 
tirapazamine. Glucose is essential for the survival of cells under hypoxia as 
deprivation induces significant cell kill. Mannose provides an alternative source of 
‘fuel’ for the survival of cells under hypoxia and further studies are required to 
determine whether the recycling of N-glycans occurs to release free mannose under 
hypoxic conditions. Finally, Ag8 is a novel inhibitor of LDH and is the first silver NHC 
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